<div class="entry-content"> 
 <p><strong>Key Takeaways:</strong></p> 
 <ul> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">XRP increased its momentum to $1.43 after SEC provides the final clearance on crypto asset classification</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">The IPO worth more than $1 billion of Evernorth Holdings is built to create the largest institutional XRP vault</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">These two moves are making XRP stronger in institutional finance and foster the adoption process</span></li> 
 </ul> 
 <p><span style="font-weight: 400;">XRP once again becomes the spotlight after strongly surging to the level of </span><a href="https://coinmarketcap.com/currencies/xrp/" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">$1.43</span></a><span style="font-weight: 400;">, thanks to two main factors: clearer legal guidance framework in the U.S. and a pushing wave from billion-dollar institutions directly relating to XRP.</span></p> 
 <p> </p>
 <div> 
  <img class="size-full wp-image-145243 aligncenter" src="https://img.bgstatic.com/spider-data/53662f407b1d2afb46606a1345912ab31774031798914.jpg" width="1200"> 
 </div>
 <p></p> 
 <div class="ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction"> 
  <div class="ez-toc-title-container"> 
   <h2 class="ez-toc-title">Table of Contents</h2> 
   <span class="ez-toc-title-toggle"></span> 
  </div> 
  <div> 
   <ul class="ez-toc-list ez-toc-list-level-1 "> 
    <li class="ez-toc-page-1 ez-toc-heading-level-2"><a class="ez-toc-link ez-toc-heading-1" href="#SEC_Moves_to_Clarify_Crypto_Rules">SEC Moves to Clarify Crypto Rules</a> 
     <ul class="ez-toc-list-level-3"> 
      <li class="ez-toc-heading-level-3"><a class="ez-toc-link ez-toc-heading-2" href="#What_the_Guidance_Covers">What the Guidance Covers</a></li> 
     </ul></li> 
    <li class="ez-toc-page-1 ez-toc-heading-level-2"><a class="ez-toc-link ez-toc-heading-3" href="#Evernorths_1B_IPO_Targets_XRP_Expansion">Evernorth’s $1B IPO Targets XRP Expansion</a></li> 
    <li class="ez-toc-page-1 ez-toc-heading-level-2"><a class="ez-toc-link ez-toc-heading-4" href="#A_New_Institutional_Vehicle_for_XRP">A New Institutional Vehicle for XRP</a> 
     <ul class="ez-toc-list-level-3"> 
      <li class="ez-toc-heading-level-3"><a class="ez-toc-link ez-toc-heading-5" href="#Key_Strategy_Elements">Key Strategy Elements</a></li> 
      <li class="ez-toc-page-1 ez-toc-heading-level-3"><a class="ez-toc-link ez-toc-heading-6" href="#Leadership_and_Backing">Leadership and Backing</a></li> 
     </ul></li> 
   </ul> 
  </div> 
 </div> 
 <h2><span class="ez-toc-section"></span>SEC Moves to Clarify Crypto Rules<span class="ez-toc-section-end"></span></h2> 
 <p><span style="font-weight: 400;">The U.S. Securities and Exchange Commission has made an important step to define how crypto assets are managed in line with federal securities law.</span></p> 
 <p><span style="font-weight: 400;">SEC </span><a href="https://www.sec.gov/files/rules/interp/2026/33-11412.pdf" target="_blank" rel="nofollow noopener"><span style="font-weight: 400;">issued</span></a><span style="font-weight: 400;"> an interpretation of the application of the current securities laws against digital assets. It divides crypto into use, structure, and functioning categories and provides renewed assessment to using the Howey Test to establish the status of an asset as a security.</span></p> 
 <p><span style="font-weight: 400;">This matters because it reduces long-standing uncertainty. The framework also describes the possibility of a crypto asset that is not a security nonetheless subject to the rules of an investment contract based upon its use or advertising.</span></p> 
 <h3><span class="ez-toc-section"></span>What the Guidance Covers<span class="ez-toc-section-end"></span></h3> 
 <ul> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Classification of crypto assets by function and structure</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Treatment of activities like staking, mining, and wrapping</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Clarification on airdrops under securities law</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Coordination with the CFTC on commodities classification</span></li> 
 </ul> 
 <p><span style="font-weight: 400;">This is not a new law, but a clearer interpretation. The market has reacted quickly, in which XRP benefits from the visibility improved with its legal status.</span></p> 
 <h2><span class="ez-toc-section"></span>Evernorth’s $1B IPO Targets XRP Expansion<span class="ez-toc-section-end"></span></h2> 
 <p><span style="font-weight: 400;">At the same time, Evernorth Holdings announced the listing plan via a SPAC deal with the target of raising over $1 billion. The company plans to use most of this fund to accumulate XRP and build what it calls the largest institutional XRP treasury.</span></p> 
 <p> </p>
 <div> 
  <img class="size-full wp-image-145241 aligncenter" src="https://img.bgstatic.com/spider-data/81c527eacb01c0e47676a3f5885859211774031800015.jpg" width="1201"> 
 </div>
 <p></p> 
 <h2><span class="ez-toc-section"></span>A New Institutional Vehicle for XRP<span class="ez-toc-section-end"></span></h2> 
 <p><span style="font-weight: 400;">Evernorth is positioning itself as a publicly traded gateway for XRP exposure. It will aggressively expand its ownership via various strategies unlike passive products.</span></p> 
 <h3><span class="ez-toc-section"></span>Key Strategy Elements<span class="ez-toc-section-end"></span></h3> 
 <ul> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Open-market XRP accumulation</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Institutional lending and liquidity provisioning</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Participation in DeFi yield opportunities</span></li> 
  <li style="font-weight: 400;"><span style="font-weight: 400;">Support for XRP ecosystem development</span></li> 
 </ul> 
 <p><span style="font-weight: 400;">The company will also operate validators, inject liquidity, and connect to the rest of the decentralized finance through the infrastructure of Ripple.</span></p> 
 <h3><span class="ez-toc-section"></span>Leadership and Backing<span class="ez-toc-section-end"></span></h3> 
 <p><span style="font-weight: 400;">Evernorth is headed by ex-Ripple executive Asheesh Birla and supported by the investments led by Ripple as well as SBI and the leading crypto investment firms. The company will be listed on Nasdaq under the ticker XRPN awaiting approval.</span></p> 
 <p><span style="font-weight: 400;">These changes are indicative of the change in the XRP among large investors. The interpretation by SEC reduces legal ambiguity and Evernorth offers a structured vehicle of exposing the market to the public. The combination of them creates a more transparent channel of institutional funds entering the XRP ecosystem.</span></p> 
</div>

Key Takeaways: XRP increased its momentum to $1.43 after SEC provides the final clearance on crypto asset classification The IPO worth more than $1 billion of Evernorth Holdings is built to create the largest institutional XRP vault These two moves are making XRP stronger in institutional finance and foster the adoption process XRP once again becomes the spotlight after strongly surging to the level of $1.43, thanks to two main factors: clearer legal guidance framework in the U.S. and a pushing wave from billion-dollar institutions directly relating to XRP. Table of Contents SEC Moves to Clarify Crypto Rules What the Guidance Covers Evernorth’s $1B IPO Targets XRP Expansion A New Institutional Vehicle for XRP Key Strategy Elements Leadership and Backing SEC Moves to Clarify Crypto Rules The U.S. Securities and Exchange Commission has made an important step to define how crypto assets are managed in line with federal securities law. SEC issued an interpretation of the application of the current securities laws against digital assets. It divides crypto into use, structure, and functioning categories and provides renewed assessment to using the Howey Test to establish the status of an asset as a security. This matters because it reduces long-standing uncertainty. The framework also describes the possibility of a crypto asset that is not a security nonetheless subject to the rules of an investment contract based upon its use or advertising. What the Guidance Covers Classification of crypto assets by function and structure Treatment of activities like staking, mining, and wrapping Clarification on airdrops under securities law Coordination with the CFTC on commodities classification This is not a new law, but a clearer interpretation. The market has reacted quickly, in which XRP benefits from the visibility improved with its legal status. Evernorth’s $1B IPO Targets XRP Expansion At the same time, Evernorth Holdings announced the listing plan via a SPAC deal with the target of raising over $1 billion. The company plans to use most of this fund to accumulate XRP and build what it calls the largest institutional XRP treasury. A New Institutional Vehicle for XRP Evernorth is positioning itself as a publicly traded gateway for XRP exposure. It will aggressively expand its ownership via various strategies unlike passive products. Key Strategy Elements Open-market XRP accumulation Institutional lending and liquidity provisioning Participation in DeFi yield opportunities Support for XRP ecosystem development The company will also operate validators, inject liquidity, and connect to the rest of the decentralized finance through the infrastructure of Ripple. Leadership and Backing Evernorth is headed by ex-Ripple executive Asheesh Birla and supported by the investments led by Ripple as well as SBI and the leading crypto investment firms. The company will be listed on Nasdaq under the ticker XRPN awaiting approval. These changes are indicative of the change in the XRP among large investors. The interpretation by SEC reduces legal ambiguity and Evernorth offers a structured vehicle of exposing the market to the public. The combination of them creates a more transparent channel of institutional funds entering the XRP ecosystem.

XRP Jumps to $1.43 as SEC Clarity and $1B Evernorth IPO Ignite Demand Surge

<h2>Q4 Earnings Overview: Waste Management Sector Insights</h2>
<p>As the fourth quarter comes to a close, we examine the financial results and major developments among waste management companies, including Montrose (NYSE:MEG) and its industry counterparts.</p>

<h3>Industry Dynamics and Challenges</h3>
<p>Waste management firms often hold permits to process hazardous materials. Many of their services are provided through contracts or are required by law, resulting in steady and reliable income. However, evolving regulations can pose challenges, sometimes rendering current services outdated or requiring significant investments to meet stricter environmental standards. Additionally, the sector is sensitive to economic trends—factors like interest rates can influence industrial activity and commercial projects, which in turn affect waste generation.</p>

<h3>Q4 Performance Summary</h3>
<p>Among the eight waste management stocks we monitor, fourth-quarter results were mixed. Collectively, their revenues matched analyst projections.</p>
<p>Despite meeting expectations, the group’s share prices have struggled, with an average decline of 7.6% since the latest earnings announcements.</p>

<h2>Montrose (NYSE:MEG)</h2>
<p>Montrose, originally established to safeguard a scenic roadway, now specializes in air quality assessments, environmental laboratory analysis, regulatory compliance, and consulting services.</p>
<p>For the quarter, Montrose posted $193.3 million in revenue—a 2.2% increase year-over-year—surpassing analyst forecasts by 2.5%. The company also exceeded expectations for both earnings per share and adjusted operating income, marking a standout quarter.</p>
<p>CEO Vijay Manthripragada reflected, “More than a year ago, we paused acquisitions to showcase our business’s resilience and strength. We anticipated that regulatory changes in the U.S. would benefit us, given our unique model and international reach. Looking back at our focused execution in 2025, we outperformed across all key metrics, achieving 13% organic revenue growth, improved EBITDA margins, and record cash flow with a 75% free cash flow conversion rate. Our strong cash flow led to year-end leverage about 0.5x lower than our initial forecast. We also enhanced cross-selling, expanded our intellectual property, and attracted top talent, positioning us well for 2026 and beyond.”</p>
<img src="https://img.bgstatic.com/spider-data/5aab9ed4caffbf22eb6c20478d47e7781774031619125.jpeg" alt="Montrose Total Revenue">
<p>Following the report, Montrose shares have declined 4.1% and are currently priced at $22.42.</p>

<h2>Top Q4 Performer: Enviri (NYSE:NVRI)</h2>
<p>Enviri, which began by cooling America’s first indoor ice rink in the 1800s, now delivers steel and waste handling solutions.</p>
<p>In the fourth quarter, Enviri generated $555 million in revenue, unchanged from the previous year but exceeding analyst estimates by 0.7%. The company delivered strong results, beating expectations for both earnings per share and EBITDA.</p>
<p>Despite its solid performance, Enviri’s stock has fallen 4.6% since the earnings release, currently trading at $18.24.</p>

<h2>Weakest Q4: Quest Resource (NASDAQ:QRHC)</h2>
<p>Quest Resource, dedicated to helping organizations improve sustainability through recycling, offers waste and recycling management services.</p>
<p>The company reported $58.91 million in revenue for the quarter, a 15.8% decrease year-over-year and 3.8% below analyst expectations. Both revenue and EBITDA fell significantly short of forecasts, marking a challenging quarter.</p>
<p>Quest Resource recorded the largest shortfall versus analyst estimates and the slowest revenue growth among its peers. Its shares have dropped 41.2% since the results, now trading at $0.85.</p>

<h2>Casella Waste Systems (NASDAQ:CWST)</h2>
<p>Casella Waste Systems began with its founder collecting trash using a pickup truck purchased with high school savings. Today, the company serves businesses, households, and government clients with a range of waste management services.</p>
<p>Casella reported $469.1 million in revenue for the quarter, up 9.7% year-over-year and in line with analyst expectations. However, the company missed estimates for adjusted operating income and EBITDA, indicating a slower quarter.</p>
<p>While Casella achieved the fastest revenue growth in the group, its full-year guidance update was the weakest. The stock has declined 16.8% since the earnings release and is now valued at $84.22.</p>

<h2>Waste Management (NYSE:WM)</h2>
<p>Based in Houston, Waste Management is a leading provider of comprehensive waste services across North America.</p>
<p>The company posted $6.31 billion in revenue for the quarter, a 7.1% year-over-year increase but 1.3% below analyst expectations. The quarter was slower, with slight misses on both revenue and adjusted operating income.</p>
<p>Despite this, Waste Management raised its full-year guidance more than any of its peers. The stock has risen 1.2% since the report and currently trades at $234.37.</p>

<h2>Market Perspective</h2>
<p>As 2025 ended and 2026 began, concerns about artificial intelligence dominated the conversation. Software companies worried that AI could undermine pricing power and reduce margins, while crypto investors questioned the long-term value of current infrastructure if AI could automate trading and asset management.</p>
<p>These anxieties led investors to shift away from tech and crypto toward safer investments. However, market sentiment quickly changed in spring 2026, as attention turned to geopolitical tensions—particularly the U.S. conflict with Iran. When geopolitical risks take precedence, investors focus less on growth and more on issues like oil supply, inflation, and global stability.</p>
<p>Looking for resilient investments? Explore our 9 Best Market-Beating Stocks—companies well-positioned for growth regardless of political or economic shifts.</p>
<p><em>The StockStory analyst team, comprised of experienced professional investors, leverages data-driven analysis and automation to deliver timely, high-quality market insights.</em></p>

Q4 Earnings Overview: Waste Management Sector Insights As the fourth quarter comes to a close, we examine the financial results and major developments among waste management companies, including Montrose (NYSE:MEG) and its industry counterparts. Industry Dynamics and Challenges Waste management firms often hold permits to process hazardous materials. Many of their services are provided through contracts or are required by law, resulting in steady and reliable income. However, evolving regulations can pose challenges, sometimes rendering current services outdated or requiring significant investments to meet stricter environmental standards. Additionally, the sector is sensitive to economic trends—factors like interest rates can influence industrial activity and commercial projects, which in turn affect waste generation. Q4 Performance Summary Among the eight waste management stocks we monitor, fourth-quarter results were mixed. Collectively, their revenues matched analyst projections. Despite meeting expectations, the group’s share prices have struggled, with an average decline of 7.6% since the latest earnings announcements. Montrose (NYSE:MEG) Montrose, originally established to safeguard a scenic roadway, now specializes in air quality assessments, environmental laboratory analysis, regulatory compliance, and consulting services. For the quarter, Montrose posted $193.3 million in revenue—a 2.2% increase year-over-year—surpassing analyst forecasts by 2.5%. The company also exceeded expectations for both earnings per share and adjusted operating income, marking a standout quarter. CEO Vijay Manthripragada reflected, “More than a year ago, we paused acquisitions to showcase our business’s resilience and strength. We anticipated that regulatory changes in the U.S. would benefit us, given our unique model and international reach. Looking back at our focused execution in 2025, we outperformed across all key metrics, achieving 13% organic revenue growth, improved EBITDA margins, and record cash flow with a 75% free cash flow conversion rate. Our strong cash flow led to year-end leverage about 0.5x lower than our initial forecast. We also enhanced cross-selling, expanded our intellectual property, and attracted top talent, positioning us well for 2026 and beyond.” Following the report, Montrose shares have declined 4.1% and are currently priced at $22.42. Top Q4 Performer: Enviri (NYSE:NVRI) Enviri, which began by cooling America’s first indoor ice rink in the 1800s, now delivers steel and waste handling solutions. In the fourth quarter, Enviri generated $555 million in revenue, unchanged from the previous year but exceeding analyst estimates by 0.7%. The company delivered strong results, beating expectations for both earnings per share and EBITDA. Despite its solid performance, Enviri’s stock has fallen 4.6% since the earnings release, currently trading at $18.24. Weakest Q4: Quest Resource (NASDAQ:QRHC) Quest Resource, dedicated to helping organizations improve sustainability through recycling, offers waste and recycling management services. The company reported $58.91 million in revenue for the quarter, a 15.8% decrease year-over-year and 3.8% below analyst expectations. Both revenue and EBITDA fell significantly short of forecasts, marking a challenging quarter. Quest Resource recorded the largest shortfall versus analyst estimates and the slowest revenue growth among its peers. Its shares have dropped 41.2% since the results, now trading at $0.85. Casella Waste Systems (NASDAQ:CWST) Casella Waste Systems began with its founder collecting trash using a pickup truck purchased with high school savings. Today, the company serves businesses, households, and government clients with a range of waste management services. Casella reported $469.1 million in revenue for the quarter, up 9.7% year-over-year and in line with analyst expectations. However, the company missed estimates for adjusted operating income and EBITDA, indicating a slower quarter. While Casella achieved the fastest revenue growth in the group, its full-year guidance update was the weakest. The stock has declined 16.8% since the earnings release and is now valued at $84.22. Waste Management (NYSE:WM) Based in Houston, Waste Management is a leading provider of comprehensive waste services across North America. The company posted $6.31 billion in revenue for the quarter, a 7.1% year-over-year increase but 1.3% below analyst expectations. The quarter was slower, with slight misses on both revenue and adjusted operating income. Despite this, Waste Management raised its full-year guidance more than any of its peers. The stock has risen 1.2% since the report and currently trades at $234.37. Market Perspective As 2025 ended and 2026 began, concerns about artificial intelligence dominated the conversation. Software companies worried that AI could undermine pricing power and reduce margins, while crypto investors questioned the long-term value of current infrastructure if AI could automate trading and asset management. These anxieties led investors to shift away from tech and crypto toward safer investments. However, market sentiment quickly changed in spring 2026, as attention turned to geopolitical tensions—particularly the U.S. conflict with Iran. When geopolitical risks take precedence, investors focus less on growth and more on issues like oil supply, inflation, and global stability. Looking for resilient investments? Explore our 9 Best Market-Beating Stocks—companies well-positioned for growth regardless of political or economic shifts. The StockStory analyst team, comprised of experienced professional investors, leverages data-driven analysis and automation to deliver timely, high-quality market insights.

A Review of Q4 Earnings for Waste Management Stocks: Comparing Montrose (NYSE:MEG) to Its Competitors

<h2>Nuclear Energy: A Massive Growth Opportunity</h2>
<p>According to analysts at <strong>Bank of America</strong>, the nuclear energy sector is on the verge of becoming a $10 trillion market.</p>
<p>The bank’s recent report highlights that nuclear power is gaining renewed attention as electricity consumption surges. Compared to other energy sources, nuclear stands out for its consistent power output, reduced carbon emissions, and impressive energy efficiency.</p>
<p>If you’re looking to benefit from the renewed focus on nuclear energy, there are two key reasons why <strong>Oklo Inc.</strong> <span class="ticker">(NYSE: OKLO)</span> stands out as a promising choice. Investing at today’s prices could have a significant long-term impact on your financial future.</p>

<h3>1. AI’s Soaring Power Needs Will Drive Nuclear Investment</h3>
<p>Electricity consumption in the United States is climbing, with projections showing a 4% annual increase through 2030. A large portion of this growth is fueled by artificial intelligence companies. By 2030, the AI sector’s share of U.S. electricity demand is expected to nearly triple, rising from 4.3% to 11.7%.</p>
<p>AI relies on data centers for processing and storage, and these facilities consume vast amounts of electricity—especially for cooling the high-performance GPUs that power AI systems. When people talk about AI’s energy appetite, they’re really referring to the immense power needs of these data centers.</p>
<p>However, the energy sector is not fully prepared to meet this new surge in demand. For years, U.S. electricity usage remained steady due to efficiency improvements, but the rapid growth of AI has changed the landscape. In response, major technology companies are investing billions in new energy projects, including bringing dormant nuclear plants back online. This urgent need for reliable power sources is a key factor behind Oklo’s potential.</p>
<img src="https://img.bgstatic.com/spider-data/6cf735029a65497462d00cf5e6d21a061774031617064.jpeg" alt="Nuclear Power Plant">
<p style="font-size:0.9em;color:#888;">Image source: Getty Images.</p>

<h3>2. Oklo’s Attractive Valuation and Associated Risks</h3>
<p>Following a steep decline of over 40%, Oklo’s market value now sits at $9.5 billion—a fraction of the $10 trillion opportunity that Bank of America envisions for the sector. If Oklo’s small modular reactor (SMR) technology gains widespread adoption among AI and tech firms, today’s share price could represent a bargain for long-term investors. However, there are several risks to consider.</p>

<ul>
  <li>Oklo faces competition from other nuclear innovators like <strong>NuScale Power</strong>, as well as large, diversified industrial companies with more resources and experience.</li>
  <li>All nuclear plants depend on uranium, and some experts predict that uranium supplies could become constrained in the coming decade, which may deter potential customers.</li>
  <li>Oklo’s relatively small size offers upside potential but also brings challenges in raising capital. Future fundraising efforts could dilute existing shareholders, impacting returns.</li>
</ul>

<p>Despite these challenges, the long-term outlook for Oklo remains positive. Major technology companies are prioritizing nuclear energy, and Oklo’s SMR technology is well-suited to deliver scalable, dependable power to AI data centers. The technology also has applications in remote areas and for military use. It’s important to recognize that this is a long-term play—Oklo’s first project isn’t expected to be operational until 2028, and delays are possible. For investors with patience and a tolerance for volatility, Oklo could be a rewarding opportunity.</p>

<h2>Is Now the Time to Invest in Oklo?</h2>
<p>Before making a decision to buy Oklo shares, consider this:</p>
<p>For example, when <strong>Netflix</strong> was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in <strong>Nvidia</strong> on April 15, 2005, would have grown to $1,094,668.</p>
<p>Currently, <em>Stock Advisor</em> boasts an average return of 911%, far outpacing the S&amp;P 500’s 186%. <strong><span>Don’t miss the latest top 10 recommendations—available with <em>Stock Advisor</em>—and join a community of investors focused on long-term success.</span></strong></p>
<p><em>*Stock Advisor returns as of March 20, 2026.</em></p>
<p><em>Ryan Vanzo does not hold positions in any of the mentioned stocks. The Motley Fool also does not own positions in these companies. For more information, see The Motley Fool’s disclosure policy.</em></p>
<p>Prediction: Buying Oklo Inc. Stock Today Could Set You Up for Life was originally published by The Motley Fool.</p>

Nuclear Energy: A Massive Growth Opportunity According to analysts at Bank of America, the nuclear energy sector is on the verge of becoming a $10 trillion market. The bank’s recent report highlights that nuclear power is gaining renewed attention as electricity consumption surges. Compared to other energy sources, nuclear stands out for its consistent power output, reduced carbon emissions, and impressive energy efficiency. If you’re looking to benefit from the renewed focus on nuclear energy, there are two key reasons why Oklo Inc. (NYSE: OKLO) stands out as a promising choice. Investing at today’s prices could have a significant long-term impact on your financial future. 1. AI’s Soaring Power Needs Will Drive Nuclear Investment Electricity consumption in the United States is climbing, with projections showing a 4% annual increase through 2030. A large portion of this growth is fueled by artificial intelligence companies. By 2030, the AI sector’s share of U.S. electricity demand is expected to nearly triple, rising from 4.3% to 11.7%. AI relies on data centers for processing and storage, and these facilities consume vast amounts of electricity—especially for cooling the high-performance GPUs that power AI systems. When people talk about AI’s energy appetite, they’re really referring to the immense power needs of these data centers. However, the energy sector is not fully prepared to meet this new surge in demand. For years, U.S. electricity usage remained steady due to efficiency improvements, but the rapid growth of AI has changed the landscape. In response, major technology companies are investing billions in new energy projects, including bringing dormant nuclear plants back online. This urgent need for reliable power sources is a key factor behind Oklo’s potential. Image source: Getty Images. 2. Oklo’s Attractive Valuation and Associated Risks Following a steep decline of over 40%, Oklo’s market value now sits at $9.5 billion—a fraction of the $10 trillion opportunity that Bank of America envisions for the sector. If Oklo’s small modular reactor (SMR) technology gains widespread adoption among AI and tech firms, today’s share price could represent a bargain for long-term investors. However, there are several risks to consider. Oklo faces competition from other nuclear innovators like NuScale Power, as well as large, diversified industrial companies with more resources and experience. All nuclear plants depend on uranium, and some experts predict that uranium supplies could become constrained in the coming decade, which may deter potential customers. Oklo’s relatively small size offers upside potential but also brings challenges in raising capital. Future fundraising efforts could dilute existing shareholders, impacting returns. Despite these challenges, the long-term outlook for Oklo remains positive. Major technology companies are prioritizing nuclear energy, and Oklo’s SMR technology is well-suited to deliver scalable, dependable power to AI data centers. The technology also has applications in remote areas and for military use. It’s important to recognize that this is a long-term play—Oklo’s first project isn’t expected to be operational until 2028, and delays are possible. For investors with patience and a tolerance for volatility, Oklo could be a rewarding opportunity. Is Now the Time to Invest in Oklo? Before making a decision to buy Oklo shares, consider this: For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in Nvidia on April 15, 2005, would have grown to $1,094,668. Currently, Stock Advisor boasts an average return of 911%, far outpacing the S&P 500’s 186%. Don’t miss the latest top 10 recommendations—available with Stock Advisor—and join a community of investors focused on long-term success. *Stock Advisor returns as of March 20, 2026. Ryan Vanzo does not hold positions in any of the mentioned stocks. The Motley Fool also does not own positions in these companies. For more information, see The Motley Fool’s disclosure policy. Prediction: Buying Oklo Inc. Stock Today Could Set You Up for Life was originally published by The Motley Fool.

Prediction: Purchasing Oklo Inc. Shares Now Might Secure Your Financial Future

<div class="rich_text_content mt-6">  <p>ChainCatcher news, according to Coinglass data, if BTC breaks through $73,001, the cumulative short liquidation intensity on mainstream CEX will reach $1.68 billions. Conversely, if BTC falls below $66,637, the cumulative long liquidation intensity on mainstream CEX will reach $1.324 billions.</p> </div>

ChainCatcher news, according to Coinglass data, if BTC breaks through $73,001, the cumulative short liquidation intensity on mainstream CEX will reach $1.68 billions. Conversely, if BTC falls below $66,637, the cumulative long liquidation intensity on mainstream CEX will reach $1.324 billions.

Data: If BTC breaks through $73,001, the cumulative short liquidation intensity on major CEXs will reach $1.68 billions.

<div class="article__content">  
 <div class="article__toc toc"> 
 </div> 
 <p>The SEC just buried regulation by enforcement. Chair Paul Atkins said the agency is taking a different approach to crypto, starting with clarity instead of enforcement.&nbsp;</p> 
 <p>The crypto market news today is a continuation of the massive regulatory move earlier this week when the SEC clarified an interpretive notice.<br>While the overall message regarding institutional crypto interest, retail traders are still looking for new coins. Even as the market logged a small correction, DeepSnitch AI continued attracting new investors who are exploring new opportunities and high-upside projects.</p> 
 <div> 
  <img width="1024" src="https://img.bgstatic.com/spider-data/73d8d7c8f3f126fb8a7f1f5e8c09be451774031458079.webp" class="wp-image-293432"> 
 </div> 
 <h2 class="wp-block-heading">End of enforcement-led policies?</h2> 
 <p>On March 19, SEC Chair Paul Atkins addressed the Practising Law Institute, clarifying how the agency intends to approach digital asset regulation following this week’s interpretive notice.</p> 
 <div> 
  <img width="1024" src="https://img.bgstatic.com/spider-data/10e38df9e0443aef4aa51d79a0f0f3a41774031458381.jpg" class="wp-image-303612"> 
 </div> 
 <p>Atkins expressed that the SEC is moving away from regulation by enforcement and toward a framework built on clear guidance first.&nbsp;</p> 
 <p>The interpretive release, issued earlier this week, following a memorandum of understanding with the CFTC, established that most cryptocurrencies are not securities under federal law. Only tokenized traditional securities remain under the SEC’s purview, while digital commodities, digital tools, NFTs, and stablecoins all fall outside it.&nbsp;</p> 
 <p>With crypto market news today turning bullish, retail traders expect the chart to follow, and are thus keeping an eye on new opportunities.</p> 
 <h2 class="wp-block-heading">Crypto assets to watch in 2026</h2> 
 <h3 class="wp-block-heading">DeepSnitch AI: Crypto market trends working in DSNT’s favor&nbsp;</h3> 
 <p>Crypto market news today shows that the longstanding regulatory fog is lifting. However, that’s not the only reason why DeepSnitch AI is popping off ahead of its March 31 launch on Uniswap.&nbsp;</p> 
 <p>Trending topics in the crypto market today were also Visa and Stripe’s push toward AI agent technology, which directly put extra attention on DeepSnitch AI.&nbsp;</p> 
 <p>The team behind the project built a powerful platform that combines five AI agents into a single dashboard. Aimed at the retail sector, DeepSnitch AI sources actionable analytics such as real-time tracking of social sentiment and FUD, info on breakout tokens, DYOR, alpha news, and so much more.</p> 
 <div> 
  <img width="1024" src="https://img.bgstatic.com/spider-data/13c2f6c44891bfab5817658496f758261774031458568.webp" class="wp-image-298560"> 
 </div> 
 <p>Most of the features are ready to go (SnitchGPT and SnitchCast agents are coming in Q2 2026), so the hype is getting palpable because DeepSnitch AI goes beyond just a quick flip.&nbsp;</p> 
 <p>Since the tools are designed for daily use, many traders anticipate DeepSnitch AI’s DSNT token to pump by a factor of 100x to 300x. This pretty much explains why the project secured $2.3M in presale, despite the bear market getting deeper.&nbsp;</p> 
 <p>The window to snag the token at an affordable $0.04577 is shrinking fast, making DeepSnitch AI’s March 31 launch one of the hottest events in crypto this month.</p> 
 <div> 
  <div class="wp-block-embed__wrapper"> 
  </div> 
 </div> 
 <h3 class="wp-block-heading">Bitcoin: Will BTC crash?</h3> 
 <p>According to CoinMarketCap, BTC ended March 19 at $70K.&nbsp;</p> 
 <p>Digital asset market news on the day led to a wave of fear as Bitcoin dipped to $68.9K. However, as the price recovered above $70K quickly, the sentiment has a neutral bias.&nbsp;</p> 
 <p>Still, the buyer conviction is dropping, which negates the previous bullish case for Bitcoin reaching $84K, leaving the realistic targets at $71.6K, followed by $72.7K.&nbsp;</p> 
 <p>If bears take full control of the price action, Bitcoin will likely decline to $68K, with the possibility of dropping to $67K.</p> 
 <h3 class="wp-block-heading">Dogecoin: What’s next for DOGE?</h3> 
 <p>DOGE closed below $0.095 on March 19, according to CoinMarketCap.&nbsp;</p> 
 <p>While the crypto market news today likely contributed to this swing, DOGE has been down for three consecutive days.&nbsp;</p> 
 <p>With the MACD histogram contracting and RSI at 48 hovering in neutral, it’s unlikely that recovery will happen soon unless DOGE closes above its 50-day EMA at $0.10.&nbsp;</p> 
 <p>Alternatively, if the current trend continues, DOGE will continue falling until it reaches $0.80.</p> 
 <h2 class="wp-block-heading">Final words: Ready for the moon?</h2> 
 <p>The interpretive framework for cryptocurrencies is in place, and even though the market is going through corrections, there is still money to be made.&nbsp;</p> 
 <p>DeepSnitch AI lists on March 31 in that environment with a live product and a community that’s been staking for months. The regulatory environment is working in its favor, which could help attract new traders while the presale window is still open.&nbsp;</p> 
 <p>If bullish institutional/regulation news doesn’t do it, the 300% bonus tokens on $30K+ with the DSNTVIP300 certainly could.&nbsp;</p> 
 <div> 
  <img width="1024" src="https://img.bgstatic.com/spider-data/c5aca4c153634350c61ebe421599c93a1774031458866.webp" class="wp-image-293599"> 
 </div> 
 <h2 class="wp-block-heading">FAQs</h2> 
 <h3 class="wp-block-heading">What did SEC Chair Atkins say about crypto regulation on Thursday?&nbsp;</h3> 
 <p>In the crypto market news today, Atkins addressed the Practicing Law Institute, confirming the SEC is abandoning regulation by enforcement in favor of clear guidance. Following this week’s interpretive release, Atkins described the notice as a beginning, with further clarity on the way as Congress works toward a market structure bill.</p> 
 <h3 class="wp-block-heading">How does the SEC’s new approach affect crypto projects launching in 2026?&nbsp;</h3> 
 <p>The removal of enforcement-led uncertainty reduces the regulatory risk that historically slowed CEX listings and institutional participation. For projects like DeepSnitch AI with confirmed TGE dates and real utility, clearer SEC guidance makes the post-listing expansion path, including CEX listings, much more straightforward.&nbsp;&nbsp;</p> 
 <h3 class="wp-block-heading">What are the key levels for Bitcoin and Dogecoin right now?&nbsp;</h3> 
 <p>BTC is holding above $68K support after pulling back below $70K, with resistance at $71K, then the 50-day EMA at $72K. DOGE is below $0.095 with the February 11 low at $0.0879 as the next support, while bulls need a close above $0.1016 to target $0.1144.</p> 
</div>

The SEC just buried regulation by enforcement. Chair Paul Atkins said the agency is taking a different approach to crypto, starting with clarity instead of enforcement. The crypto market news today is a continuation of the massive regulatory move earlier this week when the SEC clarified an interpretive notice. While the overall message regarding institutional crypto interest, retail traders are still looking for new coins. Even as the market logged a small correction, DeepSnitch AI continued attracting new investors who are exploring new opportunities and high-upside projects. End of enforcement-led policies? On March 19, SEC Chair Paul Atkins addressed the Practising Law Institute, clarifying how the agency intends to approach digital asset regulation following this week’s interpretive notice. Atkins expressed that the SEC is moving away from regulation by enforcement and toward a framework built on clear guidance first. The interpretive release, issued earlier this week, following a memorandum of understanding with the CFTC, established that most cryptocurrencies are not securities under federal law. Only tokenized traditional securities remain under the SEC’s purview, while digital commodities, digital tools, NFTs, and stablecoins all fall outside it. With crypto market news today turning bullish, retail traders expect the chart to follow, and are thus keeping an eye on new opportunities. Crypto assets to watch in 2026 DeepSnitch AI: Crypto market trends working in DSNT’s favor Crypto market news today shows that the longstanding regulatory fog is lifting. However, that’s not the only reason why DeepSnitch AI is popping off ahead of its March 31 launch on Uniswap. Trending topics in the crypto market today were also Visa and Stripe’s push toward AI agent technology, which directly put extra attention on DeepSnitch AI. The team behind the project built a powerful platform that combines five AI agents into a single dashboard. Aimed at the retail sector, DeepSnitch AI sources actionable analytics such as real-time tracking of social sentiment and FUD, info on breakout tokens, DYOR, alpha news, and so much more. Most of the features are ready to go (SnitchGPT and SnitchCast agents are coming in Q2 2026), so the hype is getting palpable because DeepSnitch AI goes beyond just a quick flip. Since the tools are designed for daily use, many traders anticipate DeepSnitch AI’s DSNT token to pump by a factor of 100x to 300x. This pretty much explains why the project secured $2.3M in presale, despite the bear market getting deeper. The window to snag the token at an affordable $0.04577 is shrinking fast, making DeepSnitch AI’s March 31 launch one of the hottest events in crypto this month. Bitcoin: Will BTC crash? According to CoinMarketCap, BTC ended March 19 at $70K. Digital asset market news on the day led to a wave of fear as Bitcoin dipped to $68.9K. However, as the price recovered above $70K quickly, the sentiment has a neutral bias. Still, the buyer conviction is dropping, which negates the previous bullish case for Bitcoin reaching $84K, leaving the realistic targets at $71.6K, followed by $72.7K. If bears take full control of the price action, Bitcoin will likely decline to $68K, with the possibility of dropping to $67K. Dogecoin: What’s next for DOGE? DOGE closed below $0.095 on March 19, according to CoinMarketCap. While the crypto market news today likely contributed to this swing, DOGE has been down for three consecutive days. With the MACD histogram contracting and RSI at 48 hovering in neutral, it’s unlikely that recovery will happen soon unless DOGE closes above its 50-day EMA at $0.10. Alternatively, if the current trend continues, DOGE will continue falling until it reaches $0.80. Final words: Ready for the moon? The interpretive framework for cryptocurrencies is in place, and even though the market is going through corrections, there is still money to be made. DeepSnitch AI lists on March 31 in that environment with a live product and a community that’s been staking for months. The regulatory environment is working in its favor, which could help attract new traders while the presale window is still open. If bullish institutional/regulation news doesn’t do it, the 300% bonus tokens on $30K+ with the DSNTVIP300 certainly could. FAQs What did SEC Chair Atkins say about crypto regulation on Thursday? In the crypto market news today, Atkins addressed the Practicing Law Institute, confirming the SEC is abandoning regulation by enforcement in favor of clear guidance. Following this week’s interpretive release, Atkins described the notice as a beginning, with further clarity on the way as Congress works toward a market structure bill. How does the SEC’s new approach affect crypto projects launching in 2026? The removal of enforcement-led uncertainty reduces the regulatory risk that historically slowed CEX listings and institutional participation. For projects like DeepSnitch AI with confirmed TGE dates and real utility, clearer SEC guidance makes the post-listing expansion path, including CEX listings, much more straightforward. What are the key levels for Bitcoin and Dogecoin right now? BTC is holding above $68K support after pulling back below $70K, with resistance at $71K, then the 50-day EMA at $72K. DOGE is below $0.095 with the February 11 low at $0.0879 as the next support, while bulls need a close above $0.1016 to target $0.1144.

Crypto Market News Today: Traders Confident DeepSnitch AI Will Go Parabolic as Crypto Makes Regulatory Strides And BTC and DOGE’s Momentum Weakens

<h2>Review of Q4 Results for Investment Banking & Brokerage Stocks</h2>
<p>As we reflect on the fourth quarter earnings for investment banking and brokerage firms, we highlight the top and bottom performers this season, including BGC (NASDAQ:BGC) and its industry counterparts.</p>

<h3>Industry Overview</h3>
<p>Investment banks and brokerages play a crucial role in raising capital, managing mergers and acquisitions, and facilitating securities trading. The sector tends to thrive during periods of economic growth, benefiting from increased corporate transactions, higher retail trading activity, and new advisory opportunities in emerging markets. However, these companies face challenges such as sensitivity to economic cycles, shrinking trading commissions due to digital platforms, and regulatory capital requirements that can limit riskier business lines.</p>

<h3>Q4 Performance Snapshot</h3>
<p>Among the 16 investment banking and brokerage stocks we monitor, the group delivered an impressive fourth quarter. Collectively, their revenues surpassed analyst forecasts by 5.9%, and guidance for the upcoming quarter met expectations.</p>
<p>Despite these strong financial results, share prices have struggled, with the group’s average stock price declining 16.4% since the latest earnings announcements.</p>

<h2>BGC (NASDAQ:BGC)</h2>
<p>Established in 1945 and named after its founder Bernard Gerald Cantor, BGC Group (NASDAQ:BGC) operates a global platform for brokerage and financial technology, enabling trading in fixed income, foreign exchange, equities, energy, and commodities.</p>
<p>BGC posted $723.3 million in revenue for the quarter, marking a 32% increase year-over-year. However, this figure was 3.7% below what analysts had anticipated, making it a softer quarter for the company.</p>
<img src="https://img.bgstatic.com/spider-data/b7257c75deba77bf07ae6a6e1b6eb4ca1774031258939.jpeg" alt="BGC Total Revenue">
<p>Of all the companies in the group, BGC missed analyst expectations by the widest margin. Interestingly, its stock has climbed 10.2% since the earnings release and is currently trading at $9.60.</p>

<h2>Top Q4 Performer: Moelis (NYSE:MC)</h2>
<p>Founded in 2007 by Ken Moelis, Moelis & Company (NYSE:MC) is an independent investment bank offering strategic and financial advisory services to corporations, financial sponsors, governments, and sovereign wealth funds.</p>
<p>Moelis reported quarterly revenue of $487.9 million, an 11.2% increase from the previous year and 10% above analyst estimates. The company exceeded expectations for both earnings per share and revenue, marking a standout quarter.</p>
<p>Despite these strong results, the market reacted negatively, with Moelis shares falling 23.9% since the earnings report. The stock is currently priced at $53.98.</p>

<h2>Charles Schwab (NYSE:SCHW)</h2>
<p>Launched in 1971 as a challenger to traditional Wall Street firms, Charles Schwab (NYSE:SCHW) is a leading wealth management and brokerage company, offering investment, banking, and advisory services to individual investors and independent advisors.</p>
<p>For the quarter, Charles Schwab generated $6.34 billion in revenue, up 18.9% year-over-year but slightly below analyst expectations by 0.6%. The company faced challenges in other segments, resulting in a mixed performance overall.</p>
<p>Following the results, Schwab’s stock has dropped 7% and is now trading at $93.90.</p>

<h2>Evercore (NYSE:EVR)</h2>
<p>Founded in 1995 with a focus on independent, client-centered advice, Evercore (NYSE:EVR) is an investment banking firm providing strategic advisory, capital markets, and wealth management services to corporations, financial sponsors, and high-net-worth clients.</p>
<p>Evercore reported $1.30 billion in revenue for the quarter, a 32.4% increase year-over-year and 16% above analyst expectations. The company also exceeded estimates for both earnings per share and revenue, delivering an outstanding quarter.</p>
<p>Despite these achievements, Evercore shares have fallen 18.8% since the earnings announcement, with the stock currently at $275.06.</p>

<h2>Perella Weinberg (NASDAQ:PWP)</h2>
<p>Established in 2006 by Joseph Perella and Peter Weinberg, Perella Weinberg Partners (NASDAQ:PWP) is a global independent advisory firm serving corporations, financial sponsors, and government entities with strategic and financial advice.</p>
<p>Perella Weinberg posted $219.2 million in revenue, a 2.9% decrease from the prior year, but still beat analyst expectations by a significant 27.7%. The company also outperformed on earnings per share and revenue estimates, making it a standout quarter.</p>
<p>Among its peers, Perella Weinberg achieved the largest positive surprise relative to analyst forecasts. However, its stock has declined 19.6% since the earnings release and is currently trading at $17.31.</p>

<h2>Market Trends and Outlook</h2>
<p>As 2025 drew to a close and 2026 began, concerns about artificial intelligence weighed on the market. Software companies worried that AI could erode pricing power and margins by making it easier to replicate complex enterprise solutions. In the cryptocurrency space, investors questioned the long-term value of current infrastructure if AI agents could autonomously trade, allocate capital, and manage wallets.</p>
<p>These anxieties prompted a shift away from technology and crypto sectors toward safer investments. However, market narratives change quickly. By spring 2026, attention turned sharply to geopolitical risks, particularly the US conflict with Iran. When geopolitics dominate, investors focus less on growth and more on issues like oil supply, inflation, and global stability.</p>

<h3>Looking for Resilient Investments?</h3>
<p>Interested in companies with strong fundamentals? Explore our Top 5 Quality Compounder Stocks—these businesses are well-positioned to grow regardless of political or economic shifts.</p>

<p><em>The StockStory analyst team, comprised of experienced professional investors, leverages quantitative analysis and automation to deliver high-quality, timely market insights.</em></p>

Review of Q4 Results for Investment Banking & Brokerage Stocks As we reflect on the fourth quarter earnings for investment banking and brokerage firms, we highlight the top and bottom performers this season, including BGC (NASDAQ:BGC) and its industry counterparts. Industry Overview Investment banks and brokerages play a crucial role in raising capital, managing mergers and acquisitions, and facilitating securities trading. The sector tends to thrive during periods of economic growth, benefiting from increased corporate transactions, higher retail trading activity, and new advisory opportunities in emerging markets. However, these companies face challenges such as sensitivity to economic cycles, shrinking trading commissions due to digital platforms, and regulatory capital requirements that can limit riskier business lines. Q4 Performance Snapshot Among the 16 investment banking and brokerage stocks we monitor, the group delivered an impressive fourth quarter. Collectively, their revenues surpassed analyst forecasts by 5.9%, and guidance for the upcoming quarter met expectations. Despite these strong financial results, share prices have struggled, with the group’s average stock price declining 16.4% since the latest earnings announcements. BGC (NASDAQ:BGC) Established in 1945 and named after its founder Bernard Gerald Cantor, BGC Group (NASDAQ:BGC) operates a global platform for brokerage and financial technology, enabling trading in fixed income, foreign exchange, equities, energy, and commodities. BGC posted $723.3 million in revenue for the quarter, marking a 32% increase year-over-year. However, this figure was 3.7% below what analysts had anticipated, making it a softer quarter for the company. Of all the companies in the group, BGC missed analyst expectations by the widest margin. Interestingly, its stock has climbed 10.2% since the earnings release and is currently trading at $9.60. Top Q4 Performer: Moelis (NYSE:MC) Founded in 2007 by Ken Moelis, Moelis & Company (NYSE:MC) is an independent investment bank offering strategic and financial advisory services to corporations, financial sponsors, governments, and sovereign wealth funds. Moelis reported quarterly revenue of $487.9 million, an 11.2% increase from the previous year and 10% above analyst estimates. The company exceeded expectations for both earnings per share and revenue, marking a standout quarter. Despite these strong results, the market reacted negatively, with Moelis shares falling 23.9% since the earnings report. The stock is currently priced at $53.98. Charles Schwab (NYSE:SCHW) Launched in 1971 as a challenger to traditional Wall Street firms, Charles Schwab (NYSE:SCHW) is a leading wealth management and brokerage company, offering investment, banking, and advisory services to individual investors and independent advisors. For the quarter, Charles Schwab generated $6.34 billion in revenue, up 18.9% year-over-year but slightly below analyst expectations by 0.6%. The company faced challenges in other segments, resulting in a mixed performance overall. Following the results, Schwab’s stock has dropped 7% and is now trading at $93.90. Evercore (NYSE:EVR) Founded in 1995 with a focus on independent, client-centered advice, Evercore (NYSE:EVR) is an investment banking firm providing strategic advisory, capital markets, and wealth management services to corporations, financial sponsors, and high-net-worth clients. Evercore reported $1.30 billion in revenue for the quarter, a 32.4% increase year-over-year and 16% above analyst expectations. The company also exceeded estimates for both earnings per share and revenue, delivering an outstanding quarter. Despite these achievements, Evercore shares have fallen 18.8% since the earnings announcement, with the stock currently at $275.06. Perella Weinberg (NASDAQ:PWP) Established in 2006 by Joseph Perella and Peter Weinberg, Perella Weinberg Partners (NASDAQ:PWP) is a global independent advisory firm serving corporations, financial sponsors, and government entities with strategic and financial advice. Perella Weinberg posted $219.2 million in revenue, a 2.9% decrease from the prior year, but still beat analyst expectations by a significant 27.7%. The company also outperformed on earnings per share and revenue estimates, making it a standout quarter. Among its peers, Perella Weinberg achieved the largest positive surprise relative to analyst forecasts. However, its stock has declined 19.6% since the earnings release and is currently trading at $17.31. Market Trends and Outlook As 2025 drew to a close and 2026 began, concerns about artificial intelligence weighed on the market. Software companies worried that AI could erode pricing power and margins by making it easier to replicate complex enterprise solutions. In the cryptocurrency space, investors questioned the long-term value of current infrastructure if AI agents could autonomously trade, allocate capital, and manage wallets. These anxieties prompted a shift away from technology and crypto sectors toward safer investments. However, market narratives change quickly. By spring 2026, attention turned sharply to geopolitical risks, particularly the US conflict with Iran. When geopolitics dominate, investors focus less on growth and more on issues like oil supply, inflation, and global stability. Looking for Resilient Investments? Interested in companies with strong fundamentals? Explore our Top 5 Quality Compounder Stocks—these businesses are well-positioned to grow regardless of political or economic shifts. The StockStory analyst team, comprised of experienced professional investors, leverages quantitative analysis and automation to deliver high-quality, timely market insights.

Investment Banking and Brokerage Shares Q4 Earnings: Comparing BGC (NASDAQ:BGC)

<h2>The Trade Desk: A Former Growth Star at a Crossroads</h2>
<p><strong>The Trade Desk</strong> <span class="ticker">(NASDAQ: TTD)</span> was once celebrated as a high-growth stock, but over the past five years, its value has dropped by nearly 70%, bringing it to its lowest point in several years. Let’s explore the reasons behind this adtech giant’s fall from favor—and why its current situation might appeal to investors who seek opportunities in overlooked stocks.</p>
<img src="https://img.bgstatic.com/spider-data/df703fbd914e3cc16f0e0dc5d395e62c1774031259441.jpeg" alt="The Trade Desk stock performance">

<h2>Understanding The Trade Desk’s Business Model</h2>
<p>The Trade Desk operates the largest independent demand-side platform (DSP) for digital advertising worldwide. DSPs enable the automated purchase of ad space across desktop, mobile, and connected TV (CTV) channels. These platforms typically collaborate with sell-side platforms (SSPs), which help publishers monetize their ad inventory.</p>
<p>Major tech firms such as <strong>Meta Platforms</strong> <span class="ticker">(NASDAQ: META)</span> and <strong>Alphabet</strong> <span class="ticker">(NASDAQ: GOOG)</span> <span class="ticker">(NASDAQ: GOOGL)</span> integrate DSPs, SSPs, and other advertising technologies into their own ecosystems. However, these companies often restrict advertisers and publishers to their proprietary networks of websites and apps. To reach audiences across the broader “open internet,” advertisers frequently turn to independent DSPs like The Trade Desk.</p>
<p>To meet these needs, The Trade Desk provides Solimar, a unified platform for data analysis, and Kokai, an AI-driven suite for campaign planning, bidding, optimization, and measurement. The company has also introduced Unified ID 2.0 (UID2) to replace traditional website cookies, and launched Ventura, a smart TV operating system featuring its own advertising inventory. Additionally, its OpenPath platform allows advertisers to connect directly with publishers, bypassing SSPs altogether.</p>

<h2>What’s Behind The Trade Desk’s Share Price Drop?</h2>
<p>Between 2020 and 2025, The Trade Desk’s revenue and adjusted EBITDA grew at compound annual rates of 28% and 33%, respectively. This impressive expansion was largely fueled by its CTV segment, which benefited from the rise of ad-supported streaming services, while growth in desktop and mobile advertising was more modest.</p>
<p>Looking ahead, analysts project that from 2025 to 2028, both revenue and adjusted EBITDA will increase at annual rates of 11%, as the CTV business continues to grow and Kokai’s AI features attract more clients. There are also reports that The Trade Desk is negotiating with OpenAI to place ads within ChatGPT.</p>
<p>Despite maintaining solid growth, The Trade Desk’s slowing momentum and current challenges in the advertising industry have likely discouraged bullish investors. However, with an enterprise value of $9.6 billion, the stock is trading at just seven times this year’s projected adjusted EBITDA—a valuation that appears attractive compared to its historical averages.</p>

<h2>Why Contrarian Investors Are Watching</h2>
<p>This situation may present an opportunity for investors who go against the crowd. If you believe The Trade Desk can continue to draw advertisers away from Meta and Google and evolve into a more diversified adtech company, the recent decline in its share price could be a compelling entry point for those willing to wait for a turnaround.</p>

<h2>Is Now the Time to Invest in The Trade Desk?</h2>
<p>Before making a decision to buy The Trade Desk shares, consider this:</p>
<ul>
  <li>The <em>Motley Fool Stock Advisor</em> team has recently selected what they consider the <strong>10 best stocks</strong> to buy right now—and The Trade Desk is not among them. The selected companies are expected to deliver significant returns in the years ahead.</li>
  <li>For example, when <strong>Netflix</strong> was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in <strong>Nvidia</strong> from April 15, 2005, would have grown to $1,094,668.*</li>
  <li>Currently, <em>Stock Advisor</em> boasts an average total return of 911%, far outpacing the S&amp;P 500’s 186%. <strong>Don’t miss the latest top 10 picks, available with <em>Stock Advisor</em>, and join a community of individual investors.</strong></li>
</ul>
<p><em>*Stock Advisor returns as of March 20, 2026.</em></p>
<p><em>Leo Sun owns shares of Meta Platforms. The Motley Fool holds positions in and recommends Alphabet, Meta Platforms, and The Trade Desk. For more details, see our disclosure policy.</em></p>
<p>The Trade Desk Just Fell to a Multi-Year Low. Contrarian Investors Are Paying Attention. was originally published by The Motley Fool.</p>

The Trade Desk: A Former Growth Star at a Crossroads The Trade Desk (NASDAQ: TTD) was once celebrated as a high-growth stock, but over the past five years, its value has dropped by nearly 70%, bringing it to its lowest point in several years. Let’s explore the reasons behind this adtech giant’s fall from favor—and why its current situation might appeal to investors who seek opportunities in overlooked stocks. Understanding The Trade Desk’s Business Model The Trade Desk operates the largest independent demand-side platform (DSP) for digital advertising worldwide. DSPs enable the automated purchase of ad space across desktop, mobile, and connected TV (CTV) channels. These platforms typically collaborate with sell-side platforms (SSPs), which help publishers monetize their ad inventory. Major tech firms such as Meta Platforms (NASDAQ: META) and Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) integrate DSPs, SSPs, and other advertising technologies into their own ecosystems. However, these companies often restrict advertisers and publishers to their proprietary networks of websites and apps. To reach audiences across the broader “open internet,” advertisers frequently turn to independent DSPs like The Trade Desk. To meet these needs, The Trade Desk provides Solimar, a unified platform for data analysis, and Kokai, an AI-driven suite for campaign planning, bidding, optimization, and measurement. The company has also introduced Unified ID 2.0 (UID2) to replace traditional website cookies, and launched Ventura, a smart TV operating system featuring its own advertising inventory. Additionally, its OpenPath platform allows advertisers to connect directly with publishers, bypassing SSPs altogether. What’s Behind The Trade Desk’s Share Price Drop? Between 2020 and 2025, The Trade Desk’s revenue and adjusted EBITDA grew at compound annual rates of 28% and 33%, respectively. This impressive expansion was largely fueled by its CTV segment, which benefited from the rise of ad-supported streaming services, while growth in desktop and mobile advertising was more modest. Looking ahead, analysts project that from 2025 to 2028, both revenue and adjusted EBITDA will increase at annual rates of 11%, as the CTV business continues to grow and Kokai’s AI features attract more clients. There are also reports that The Trade Desk is negotiating with OpenAI to place ads within ChatGPT. Despite maintaining solid growth, The Trade Desk’s slowing momentum and current challenges in the advertising industry have likely discouraged bullish investors. However, with an enterprise value of $9.6 billion, the stock is trading at just seven times this year’s projected adjusted EBITDA—a valuation that appears attractive compared to its historical averages. Why Contrarian Investors Are Watching This situation may present an opportunity for investors who go against the crowd. If you believe The Trade Desk can continue to draw advertisers away from Meta and Google and evolve into a more diversified adtech company, the recent decline in its share price could be a compelling entry point for those willing to wait for a turnaround. Is Now the Time to Invest in The Trade Desk? Before making a decision to buy The Trade Desk shares, consider this: The Motley Fool Stock Advisor team has recently selected what they consider the 10 best stocks to buy right now—and The Trade Desk is not among them. The selected companies are expected to deliver significant returns in the years ahead. For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in Nvidia from April 15, 2005, would have grown to $1,094,668.* Currently, Stock Advisor boasts an average total return of 911%, far outpacing the S&P 500’s 186%. Don’t miss the latest top 10 picks, available with Stock Advisor, and join a community of individual investors. *Stock Advisor returns as of March 20, 2026. Leo Sun owns shares of Meta Platforms. The Motley Fool holds positions in and recommends Alphabet, Meta Platforms, and The Trade Desk. For more details, see our disclosure policy. The Trade Desk Just Fell to a Multi-Year Low. Contrarian Investors Are Paying Attention. was originally published by The Motley Fool.

The Trade Desk Has Dropped to Its Lowest Point in Years. Value Investors Are Taking Notice.

<h2>Novo Nordisk Shares Plunge: Is It an Opportunity for Investors?</h2>
<p>Over the past year, Danish pharmaceutical company <strong>Novo Nordisk</strong> (<span class="ticker">NYSE: NVO</span>) has seen its stock price fall dramatically, losing more than half its value. This steep decline comes on the heels of disappointing financial results and a less-than-optimistic outlook from the company.</p>
<p>The stock has now dropped to levels not seen since early 2021—before its weight loss medication, Wegovy, received regulatory approval that summer. A combination of factors has contributed to this significant downturn.</p>
<p>Investor sentiment toward Novo Nordisk has been overwhelmingly negative. But the key question remains: has the pessimism gone too far, and is the stock now so undervalued that it presents a compelling buying opportunity in the healthcare sector?</p>
<img src="https://img.bgstatic.com/spider-data/ce81f8163a68e29d936b01a8df6a5f461774031258717.jpeg" alt="Novo Nordisk stock chart">
<p><em>Image source: Getty Images.</em></p>

<h2>Novo Nordisk Faces Challenges, But Its Story Isn't Over</h2>
<p>Novo Nordisk is navigating a difficult period, marked by a leadership change and a significant reduction in its financial outlook for the year. The company anticipates that revenue could fall by up to 13% this year, despite the introduction of a new oral version of Wegovy.</p>
<p>While Novo Nordisk is under pressure to lower prices, management is confident that more competitive pricing, attracting new customers, and expanding market share could pave the way for stronger growth ahead. The company recently partnered with telehealth provider <strong>Hims &amp; Hers Health</strong> to offer its GLP-1 products through the Hims platform—a move that could boost sales beyond current expectations, especially after the recent guidance downgrade.</p>

<h2>Is Novo Nordisk Stock a Bargain Right Now?</h2>
<p>Markets often overvalue thriving companies and undervalue those facing difficulties. For long-term investors, this can create opportunities to buy quality businesses at discounted prices. Legendary investor Warren Buffett has noted that investing in companies experiencing temporary setbacks can be highly rewarding, especially when the market has priced them too low.</p>
<p>In Novo Nordisk’s case, the current challenges appear to be short-term obstacles. The company remains fundamentally strong, and its shares are now trading at just 10 times earnings—a remarkably low valuation for a leading healthcare firm. This offers investors a significant margin of safety and the potential for substantial gains if the company rebounds.</p>

<h2>Long-Term Outlook: Should You Consider Novo Nordisk?</h2>
<p>Although Novo Nordisk is enduring a tough year, those willing to invest for the long term may find this an attractive entry point.</p>

<h3>Key Considerations Before Investing</h3>
<ul>
  <li>The Motley Fool Stock Advisor team has recently highlighted what they believe are the <strong>10 best stocks</strong> to buy right now—and Novo Nordisk is not on that list. The selected stocks are expected to deliver impressive returns in the years ahead.</li>
  <li>For example, when <strong>Netflix</strong> was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in <strong>Nvidia</strong> from April 15, 2005, would have grown to $1,094,668.</li>
  <li>Currently, <em>Stock Advisor</em> boasts an average return of 911%, far outpacing the S&amp;P 500’s 186%. <strong>Don’t miss the latest top 10 picks, available through <em>Stock Advisor</em>, and join a community of individual investors.</strong></li>
</ul>
<p><em>*Stock Advisor performance as of March 20, 2026.</em></p>
<p><em>David Jagielski, CPA holds shares in Novo Nordisk. The Motley Fool owns and recommends Hims &amp; Hers Health, and also recommends Novo Nordisk. For more details, see The Motley Fool’s disclosure policy.</em></p>
<p>Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? was originally published by The Motley Fool.</p>

Novo Nordisk Shares Plunge: Is It an Opportunity for Investors? Over the past year, Danish pharmaceutical company Novo Nordisk (NYSE: NVO) has seen its stock price fall dramatically, losing more than half its value. This steep decline comes on the heels of disappointing financial results and a less-than-optimistic outlook from the company. The stock has now dropped to levels not seen since early 2021—before its weight loss medication, Wegovy, received regulatory approval that summer. A combination of factors has contributed to this significant downturn. Investor sentiment toward Novo Nordisk has been overwhelmingly negative. But the key question remains: has the pessimism gone too far, and is the stock now so undervalued that it presents a compelling buying opportunity in the healthcare sector? Image source: Getty Images. Novo Nordisk Faces Challenges, But Its Story Isn't Over Novo Nordisk is navigating a difficult period, marked by a leadership change and a significant reduction in its financial outlook for the year. The company anticipates that revenue could fall by up to 13% this year, despite the introduction of a new oral version of Wegovy. While Novo Nordisk is under pressure to lower prices, management is confident that more competitive pricing, attracting new customers, and expanding market share could pave the way for stronger growth ahead. The company recently partnered with telehealth provider Hims & Hers Health to offer its GLP-1 products through the Hims platform—a move that could boost sales beyond current expectations, especially after the recent guidance downgrade. Is Novo Nordisk Stock a Bargain Right Now? Markets often overvalue thriving companies and undervalue those facing difficulties. For long-term investors, this can create opportunities to buy quality businesses at discounted prices. Legendary investor Warren Buffett has noted that investing in companies experiencing temporary setbacks can be highly rewarding, especially when the market has priced them too low. In Novo Nordisk’s case, the current challenges appear to be short-term obstacles. The company remains fundamentally strong, and its shares are now trading at just 10 times earnings—a remarkably low valuation for a leading healthcare firm. This offers investors a significant margin of safety and the potential for substantial gains if the company rebounds. Long-Term Outlook: Should You Consider Novo Nordisk? Although Novo Nordisk is enduring a tough year, those willing to invest for the long term may find this an attractive entry point. Key Considerations Before Investing The Motley Fool Stock Advisor team has recently highlighted what they believe are the 10 best stocks to buy right now—and Novo Nordisk is not on that list. The selected stocks are expected to deliver impressive returns in the years ahead. For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in Nvidia from April 15, 2005, would have grown to $1,094,668. Currently, Stock Advisor boasts an average return of 911%, far outpacing the S&P 500’s 186%. Don’t miss the latest top 10 picks, available through Stock Advisor, and join a community of individual investors. *Stock Advisor performance as of March 20, 2026. David Jagielski, CPA holds shares in Novo Nordisk. The Motley Fool owns and recommends Hims & Hers Health, and also recommends Novo Nordisk. For more details, see The Motley Fool’s disclosure policy. Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? was originally published by The Motley Fool.

Down Approaching Its Lowest Point in 5 Years, Is Novo Nordisk Stock a Bargain You Shouldn't Miss?

<h2>UK Refineries Face Shutdown Threat Amid Carbon Tax Dispute</h2>
<img src="https://img.bgstatic.com/spider-data/c66b63860b6f374939a93368fe3469d91774031259005.jpeg" alt="UK refinery image">
<p>Rachel Reeves has declined to introduce a carbon tax on imported fuel, a move that industry leaders warn could force Britain’s remaining petrol refineries to close.</p>
<p>On Friday, Fuels Industry UK cautioned that the country’s final four refineries are in jeopardy after the Chancellor dismissed proposals for a carbon levy on foreign fuel.</p>
<p>Elizabeth de Jong, CEO of Fuels Industry UK, stated that this decision “makes it increasingly likely that the UK will eventually rely entirely on imported fuel.”</p>
<p>She added, “This is not a prudent approach for a major economy, especially during times of global uncertainty and heightened geopolitical tensions.”</p>
<p>This alert comes as the world grapples with a fuel crisis, with disruptions in Gulf oil supplies driving up petrol and diesel prices and raising fears of shortages.</p>
<p>The industry group has advocated for expanding the carbon tax on high-emission imports to include petrol and diesel, aiming to support struggling UK refineries.</p>
<p>British refineries contend with some of Europe’s highest electricity costs, making it difficult to compete with cheaper imports.</p>
<p>Despite ministers emphasizing the importance of maintaining domestic refineries amid Middle East conflicts affecting global energy markets, the government has opted against the tax.</p>
<p>In correspondence with the industry, the Exchequer Secretary described the decision as “difficult,” citing concerns about increased costs for businesses and households.</p>
<p>Fuels Industry UK argues that the Treasury’s refusal to extend the Carbon Border Adjustment Mechanism (CBAM) puts the nation’s last four oil refineries at risk of closure.</p>

<h3>Government Holds the Key</h3>
<p>Refineries are already under pressure from rising clean energy costs, while high-carbon imports continue to enter the UK without tariffs.</p>
<p>Scotland’s final oil refinery in Grangemouth shut down last year, and the Lindsey refinery, acquired by Phillips 66 in January, has also been idled.</p>
<p>Ms de Jong characterized the Treasury’s stance as a “political decision,” emphasizing that only the government can choose to extend the tax.</p>
<p>She remarked, “By refusing to implement a 2028 CBAM, the Treasury is knowingly worsening the competitive position of UK refineries.”</p>
<p>The government’s letter indicated that expanding the tax in the future remains a possibility.</p>
<p>The conflict in the Middle East has driven up global oil and gas prices, resulting in higher costs for motorists at the pump.</p>
<p>According to RAC data, average petrol prices have climbed nearly 12p (9%) since the conflict began, reaching 144.51p per litre. Diesel has surged by twice that amount to 166.24p, with a 2p increase in just the past two days.</p>

<h3>Rising Costs for Drivers</h3>
<p>The spike in fuel prices means that filling a typical family car with unleaded now costs £6.40 more than it did at the start of March, while diesel drivers are paying an extra £13.</p>
<p>Simon Williams, head of policy at the RAC, commented, “With oil prices consistently above $100 a barrel this week, unfortunately, further increases seem almost certain as we head into next week.”</p>
<p>He predicted, “The average price for a litre of unleaded could soon hit 150p, and diesel may reach 180p by Easter. As many people rely heavily on their cars, household budgets are coming under increasing strain.”</p>
<p>The Treasury has been approached for a response.</p>

UK Refineries Face Shutdown Threat Amid Carbon Tax Dispute Rachel Reeves has declined to introduce a carbon tax on imported fuel, a move that industry leaders warn could force Britain’s remaining petrol refineries to close. On Friday, Fuels Industry UK cautioned that the country’s final four refineries are in jeopardy after the Chancellor dismissed proposals for a carbon levy on foreign fuel. Elizabeth de Jong, CEO of Fuels Industry UK, stated that this decision “makes it increasingly likely that the UK will eventually rely entirely on imported fuel.” She added, “This is not a prudent approach for a major economy, especially during times of global uncertainty and heightened geopolitical tensions.” This alert comes as the world grapples with a fuel crisis, with disruptions in Gulf oil supplies driving up petrol and diesel prices and raising fears of shortages. The industry group has advocated for expanding the carbon tax on high-emission imports to include petrol and diesel, aiming to support struggling UK refineries. British refineries contend with some of Europe’s highest electricity costs, making it difficult to compete with cheaper imports. Despite ministers emphasizing the importance of maintaining domestic refineries amid Middle East conflicts affecting global energy markets, the government has opted against the tax. In correspondence with the industry, the Exchequer Secretary described the decision as “difficult,” citing concerns about increased costs for businesses and households. Fuels Industry UK argues that the Treasury’s refusal to extend the Carbon Border Adjustment Mechanism (CBAM) puts the nation’s last four oil refineries at risk of closure. Government Holds the Key Refineries are already under pressure from rising clean energy costs, while high-carbon imports continue to enter the UK without tariffs. Scotland’s final oil refinery in Grangemouth shut down last year, and the Lindsey refinery, acquired by Phillips 66 in January, has also been idled. Ms de Jong characterized the Treasury’s stance as a “political decision,” emphasizing that only the government can choose to extend the tax. She remarked, “By refusing to implement a 2028 CBAM, the Treasury is knowingly worsening the competitive position of UK refineries.” The government’s letter indicated that expanding the tax in the future remains a possibility. The conflict in the Middle East has driven up global oil and gas prices, resulting in higher costs for motorists at the pump. According to RAC data, average petrol prices have climbed nearly 12p (9%) since the conflict began, reaching 144.51p per litre. Diesel has surged by twice that amount to 166.24p, with a 2p increase in just the past two days. Rising Costs for Drivers The spike in fuel prices means that filling a typical family car with unleaded now costs £6.40 more than it did at the start of March, while diesel drivers are paying an extra £13. Simon Williams, head of policy at the RAC, commented, “With oil prices consistently above $100 a barrel this week, unfortunately, further increases seem almost certain as we head into next week.” He predicted, “The average price for a litre of unleaded could soon hit 150p, and diesel may reach 180p by Easter. As many people rely heavily on their cars, household budgets are coming under increasing strain.” The Treasury has been approached for a response.

Petroleum refineries may be forced to shut down due to Reeves' proposals, the industry cautions

<h2>Therapeutics Sector Q4 Overview</h2>
<p>Quarterly earnings reports can provide valuable insight into where a company is headed in the near future. With the fourth quarter now complete, let's review the performance of BioMarin Pharmaceutical (NASDAQ:BMRN) and its industry peers.</p>
<p>Therapeutic companies, which focus on developing innovative treatments for a range of diseases, are benefiting from advancements in precision medicine—such as AI-driven drug discovery—and increasing demand for therapies targeting rare conditions. However, these firms also face challenges, including heightened scrutiny over drug pricing, regulatory uncertainties, and stiff competition from larger pharmaceutical players.</p>

<h3>Sector Performance Highlights</h3>
<p>Among the 11 therapeutics stocks monitored, the group delivered a robust fourth quarter, collectively surpassing analyst revenue forecasts by 7.1%.</p>
<p>Despite these positive results, share prices across the sector have remained relatively stable, with little movement following the earnings announcements.</p>

<h2>BioMarin Pharmaceutical (NASDAQ:BMRN)</h2>
<p>BioMarin Pharmaceutical is recognized for its groundbreaking therapies that address the underlying causes of rare genetic disorders, particularly in pediatric patients—often providing solutions where none previously existed.</p>
<p>For the quarter, BioMarin reported revenue of $874.6 million, marking a 17% increase year-over-year and exceeding analyst projections by 4.8%. However, the company fell short of full-year EPS expectations, making this a slower period despite the revenue beat.</p>
<p>Alexander Hardy, BioMarin’s President and CEO, commented, “In 2025, our operational excellence drove strong financial results, including double-digit revenue growth, solid profitability, and rising cash flow. We also advanced several pipeline therapies and concluded the year with the acquisition of Amicus.”</p>
<img src="https://img.bgstatic.com/spider-data/b2006accbbe5aa18bf59a4293986a0ab1774031258546.jpeg" alt="BioMarin Pharmaceutical Total Revenue">
<p>BioMarin provided the weakest full-year guidance among its peers, which has contributed to a 12% decline in its stock price since the report, now trading at $55.37.</p>
<p>Curious if BioMarin is a buy at these levels?</p>

<h2>Top Performer in Q4: Novavax (NASDAQ:NVAX)</h2>
<p>Novavax stands out for its nanoparticle technology, which mimics the structure of disease-causing agents. The company specializes in protein-based vaccines for infectious diseases, with a primary focus on COVID-19 and combination respiratory vaccines.</p>
<p>Novavax posted revenue of $147.1 million for the quarter, a remarkable 66.6% increase from the previous year and an impressive 57.4% above analyst expectations. The company not only exceeded revenue forecasts but also delivered a strong earnings beat.</p>
<p>Novavax achieved the highest revenue growth and the largest beat of analyst estimates among its peers. The market responded positively, with shares rising 2.4% since the results, currently priced at $9.76.</p>
<p>Interested in Novavax’s outlook?</p>

<h2>Weakest Q4: United Therapeutics (NASDAQ:UTHR)</h2>
<p>United Therapeutics was founded by a mother seeking a cure for her daughter’s pulmonary arterial hypertension. The company develops therapies for chronic lung diseases and other serious conditions, with a particular emphasis on pulmonary hypertension treatments.</p>
<p>In the fourth quarter, United Therapeutics reported $790.2 million in revenue, up 7.4% year-over-year but 2.5% below analyst estimates. The company missed revenue expectations, making it the weakest performer against analyst forecasts in the group.</p>
<p>Despite the earnings miss, United Therapeutics’ stock has climbed 11.3% since the report and is now trading at $527.05.</p>
<p></p>

<h2>Halozyme Therapeutics (NASDAQ:HALO)</h2>
<p>Halozyme Therapeutics is known for its ENHANZE technology, which enables injectable drugs to be administered subcutaneously in minutes rather than hours via intravenous infusion. The company develops and licenses this proprietary platform to other drugmakers.</p>
<p>For the quarter, Halozyme reported revenue of $451.8 million, a 51.6% year-over-year increase and 0.6% above analyst expectations. However, the company missed both quarterly and full-year EPS estimates, making it a softer quarter overall.</p>
<p>Shares of Halozyme have dropped 21.1% since the earnings release, with the stock now trading at $63.53.</p>
<p></p>

<h2>Moderna (NASDAQ:MRNA)</h2>
<p>Moderna gained worldwide recognition during the COVID-19 pandemic for developing one of the first effective mRNA vaccines. The company continues to advance mRNA-based medicines that prompt the body to produce therapeutic or preventive proteins for a variety of diseases.</p>
<p>Moderna reported $678 million in revenue for the quarter, a 29.8% decrease from the prior year. Despite the decline, revenue exceeded analyst expectations by 2.7%, and the company also beat EPS estimates.</p>
<p>Moderna experienced the slowest revenue growth among its peers, but its stock has surged 30.5% since the earnings announcement, now trading at $52.34.</p>
<p></p>

<h2>Market Trends and Outlook</h2>
<p>As 2025 drew to a close and 2026 began, concerns about artificial intelligence began to weigh on the market. In the software sector, there were fears that AI would reduce pricing power and margins by making it easier to replicate complex enterprise solutions. Crypto investors faced similar anxieties, questioning the long-term value of current infrastructure if AI could autonomously manage trading and capital allocation.</p>
<p>These worries prompted investors to shift away from technology and crypto, seeking safer investments. However, market narratives change quickly. By spring 2026, attention turned sharply to geopolitical risks, particularly the US conflict with Iran. When geopolitics dominate, investor focus shifts from growth prospects to concerns about oil supply, inflation, and global stability.</p>
<p>Looking for resilient investment opportunities? Explore our Hidden Gem Stocks—companies with strong fundamentals that are well-positioned for growth regardless of political or economic shifts.</p>
<p><em>The StockStory analyst team, comprised of experienced professional investors, leverages quantitative research and automation to deliver timely, high-quality market insights.</em></p>

Therapeutics Sector Q4 Overview Quarterly earnings reports can provide valuable insight into where a company is headed in the near future. With the fourth quarter now complete, let's review the performance of BioMarin Pharmaceutical (NASDAQ:BMRN) and its industry peers. Therapeutic companies, which focus on developing innovative treatments for a range of diseases, are benefiting from advancements in precision medicine—such as AI-driven drug discovery—and increasing demand for therapies targeting rare conditions. However, these firms also face challenges, including heightened scrutiny over drug pricing, regulatory uncertainties, and stiff competition from larger pharmaceutical players. Sector Performance Highlights Among the 11 therapeutics stocks monitored, the group delivered a robust fourth quarter, collectively surpassing analyst revenue forecasts by 7.1%. Despite these positive results, share prices across the sector have remained relatively stable, with little movement following the earnings announcements. BioMarin Pharmaceutical (NASDAQ:BMRN) BioMarin Pharmaceutical is recognized for its groundbreaking therapies that address the underlying causes of rare genetic disorders, particularly in pediatric patients—often providing solutions where none previously existed. For the quarter, BioMarin reported revenue of $874.6 million, marking a 17% increase year-over-year and exceeding analyst projections by 4.8%. However, the company fell short of full-year EPS expectations, making this a slower period despite the revenue beat. Alexander Hardy, BioMarin’s President and CEO, commented, “In 2025, our operational excellence drove strong financial results, including double-digit revenue growth, solid profitability, and rising cash flow. We also advanced several pipeline therapies and concluded the year with the acquisition of Amicus.” BioMarin provided the weakest full-year guidance among its peers, which has contributed to a 12% decline in its stock price since the report, now trading at $55.37. Curious if BioMarin is a buy at these levels? Top Performer in Q4: Novavax (NASDAQ:NVAX) Novavax stands out for its nanoparticle technology, which mimics the structure of disease-causing agents. The company specializes in protein-based vaccines for infectious diseases, with a primary focus on COVID-19 and combination respiratory vaccines. Novavax posted revenue of $147.1 million for the quarter, a remarkable 66.6% increase from the previous year and an impressive 57.4% above analyst expectations. The company not only exceeded revenue forecasts but also delivered a strong earnings beat. Novavax achieved the highest revenue growth and the largest beat of analyst estimates among its peers. The market responded positively, with shares rising 2.4% since the results, currently priced at $9.76. Interested in Novavax’s outlook? Weakest Q4: United Therapeutics (NASDAQ:UTHR) United Therapeutics was founded by a mother seeking a cure for her daughter’s pulmonary arterial hypertension. The company develops therapies for chronic lung diseases and other serious conditions, with a particular emphasis on pulmonary hypertension treatments. In the fourth quarter, United Therapeutics reported $790.2 million in revenue, up 7.4% year-over-year but 2.5% below analyst estimates. The company missed revenue expectations, making it the weakest performer against analyst forecasts in the group. Despite the earnings miss, United Therapeutics’ stock has climbed 11.3% since the report and is now trading at $527.05. Halozyme Therapeutics (NASDAQ:HALO) Halozyme Therapeutics is known for its ENHANZE technology, which enables injectable drugs to be administered subcutaneously in minutes rather than hours via intravenous infusion. The company develops and licenses this proprietary platform to other drugmakers. For the quarter, Halozyme reported revenue of $451.8 million, a 51.6% year-over-year increase and 0.6% above analyst expectations. However, the company missed both quarterly and full-year EPS estimates, making it a softer quarter overall. Shares of Halozyme have dropped 21.1% since the earnings release, with the stock now trading at $63.53. Moderna (NASDAQ:MRNA) Moderna gained worldwide recognition during the COVID-19 pandemic for developing one of the first effective mRNA vaccines. The company continues to advance mRNA-based medicines that prompt the body to produce therapeutic or preventive proteins for a variety of diseases. Moderna reported $678 million in revenue for the quarter, a 29.8% decrease from the prior year. Despite the decline, revenue exceeded analyst expectations by 2.7%, and the company also beat EPS estimates. Moderna experienced the slowest revenue growth among its peers, but its stock has surged 30.5% since the earnings announcement, now trading at $52.34. Market Trends and Outlook As 2025 drew to a close and 2026 began, concerns about artificial intelligence began to weigh on the market. In the software sector, there were fears that AI would reduce pricing power and margins by making it easier to replicate complex enterprise solutions. Crypto investors faced similar anxieties, questioning the long-term value of current infrastructure if AI could autonomously manage trading and capital allocation. These worries prompted investors to shift away from technology and crypto, seeking safer investments. However, market narratives change quickly. By spring 2026, attention turned sharply to geopolitical risks, particularly the US conflict with Iran. When geopolitics dominate, investor focus shifts from growth prospects to concerns about oil supply, inflation, and global stability. Looking for resilient investment opportunities? Explore our Hidden Gem Stocks—companies with strong fundamentals that are well-positioned for growth regardless of political or economic shifts. The StockStory analyst team, comprised of experienced professional investors, leverages quantitative research and automation to deliver timely, high-quality market insights.

Q4 Financial Results Overview: BioMarin Pharmaceutical (NASDAQ:BMRN) Compared to Other Therapeutics Stocks

<div class="entry-content rbct clearfix is-highlight-shares"> 
 <p style="text-align: justify">Phong Le, President and CEO of strategy firm MicroStrategy, heads the world’s largest institutional holder of Bitcoin. In recent statements, Le highlighted Morgan Stanley’s groundbreaking spot Bitcoin ETF application, predicting that, should portfolios diversify at moderate rates, the market could see up to $160 billion in new demand for Bitcoin investments.</p> 
 <h2 class="rb-heading-index-0-218336">Morgan Stanley’s ETF Initiative and Institutional Interest</h2> 
 <p style="text-align: justify">Morgan Stanley, one of America’s financial powerhouses managing $8 trillion in assets, is preparing to launch a spot Bitcoin ETF under the ticker “MSBT.” According to regulatory filings, the fund will initially be composed of units representing 10,000 shares, and the product will kick off with a base of 50,000 shares in its opening phase.</p> 
 <div class="ruby-table-contents rbtoc table-left table-fw-single-col"> 
 </div> 
 <div class="toc-content"> 
  <a href="#morgan-stanleys-etf-initiative-and-institutional-interest" class="table-link no-link anchor-link h5">Morgan Stanley’s ETF Initiative and Institutional Interest</a> 
  <a href="#fund-structure-and-service-providers" class="table-link no-link anchor-link h5">Fund Structure and Service Providers</a> 
  <a href="#investor-appeal-and-sector-impact" class="table-link no-link anchor-link h5">Investor Appeal and Sector Impact</a> 
 </div> 
</div> 
<p style="text-align: justify">Phong Le underscored that allocating just 2% of institutional portfolios to Bitcoin could generate approximately $160 billion in potential demand. This figure is nearly triple the size of iShares Bitcoin Trust, currently among the largest spot Bitcoin ETFs in the market.</p> 
<h2 class="rb-heading-index-1-218336">Fund Structure and Service Providers</h2> 
<p style="text-align: justify">The planned Morgan Stanley ETF will hold physical Bitcoin directly. For fund operations, BNY Mellon will provide cash custody, administration, and transfer services. Meanwhile, Coinbase has been chosen as the provider for Bitcoin custody and primary brokerage functions. Morgan Stanley has designed the ETF to comply closely with the standards of new-generation spot Bitcoin funds in the U.S.</p> 
<p style="text-align: justify">Filing documents detail a unit-based share creation system, with initial funding close to $1 million. The bank also revealed that it purchased two shares this month as part of oversight and regulatory compliance before the official launch.</p> 
<h2 class="rb-heading-index-2-218336">Investor Appeal and Sector Impact</h2> 
<p style="text-align: justify">Phong Le emphasized that institutional adoption of Bitcoin could catalyze significant capital flows across the industry. The portfolio management division at Morgan Stanley suggests an allocation between zero and four percent for Bitcoin exposure, adjusting recommendations according to individual client risk profiles.</p> 
<blockquote> 
 <p>“Morgan Stanley Wealth Management oversees $8 trillion in assets and advocates a 0–4% Bitcoin allocation. A 2% ratio amounts to $160 billion. MSBT could symbolize this potential,” Le noted.</p> 
</blockquote> 
<p style="text-align: justify">So far in 2024, spot Bitcoin ETFs available in the U.S. have attracted over $50 billion in investment. However, adoption among advisory clients has varied, shaped by internal policies and client-specific demands within the sector.</p> 
<p style="text-align: justify">With the launch of this product, Morgan Stanley will allow its clients direct access to spot Bitcoin ETFs, potentially increasing the bank’s influence in the expanding digital asset market. Meanwhile, the U.S. Securities and Exchange Commission has yet to announce a clearer timeline for product approval, leaving the outcome uncertain.</p> 
<div></div>


Phong Le, President and CEO of strategy firm MicroStrategy, heads the world’s largest institutional holder of Bitcoin. In recent statements, Le highlighted Morgan Stanley’s groundbreaking spot Bitcoin ETF application, predicting that, should portfolios diversify at moderate rates, the market could see up to $160 billion in new demand for Bitcoin investments. Morgan Stanley’s ETF Initiative and Institutional Interest Morgan Stanley, one of America’s financial powerhouses managing $8 trillion in assets, is preparing to launch a spot Bitcoin ETF under the ticker “MSBT.” According to regulatory filings, the fund will initially be composed of units representing 10,000 shares, and the product will kick off with a base of 50,000 shares in its opening phase. Morgan Stanley’s ETF Initiative and Institutional Interest Fund Structure and Service Providers Investor Appeal and Sector Impact Phong Le underscored that allocating just 2% of institutional portfolios to Bitcoin could generate approximately $160 billion in potential demand. This figure is nearly triple the size of iShares Bitcoin Trust, currently among the largest spot Bitcoin ETFs in the market. Fund Structure and Service Providers The planned Morgan Stanley ETF will hold physical Bitcoin directly. For fund operations, BNY Mellon will provide cash custody, administration, and transfer services. Meanwhile, Coinbase has been chosen as the provider for Bitcoin custody and primary brokerage functions. Morgan Stanley has designed the ETF to comply closely with the standards of new-generation spot Bitcoin funds in the U.S. Filing documents detail a unit-based share creation system, with initial funding close to $1 million. The bank also revealed that it purchased two shares this month as part of oversight and regulatory compliance before the official launch. Investor Appeal and Sector Impact Phong Le emphasized that institutional adoption of Bitcoin could catalyze significant capital flows across the industry. The portfolio management division at Morgan Stanley suggests an allocation between zero and four percent for Bitcoin exposure, adjusting recommendations according to individual client risk profiles. “Morgan Stanley Wealth Management oversees $8 trillion in assets and advocates a 0–4% Bitcoin allocation. A 2% ratio amounts to $160 billion. MSBT could symbolize this potential,” Le noted. So far in 2024, spot Bitcoin ETFs available in the U.S. have attracted over $50 billion in investment. However, adoption among advisory clients has varied, shaped by internal policies and client-specific demands within the sector. With the launch of this product, Morgan Stanley will allow its clients direct access to spot Bitcoin ETFs, potentially increasing the bank’s influence in the expanding digital asset market. Meanwhile, the U.S. Securities and Exchange Commission has yet to announce a clearer timeline for product approval, leaving the outcome uncertain.

Morgan Stanley Targets $160 Billion Demand with Bitcoin ETF Strategy

<h2>Money Markets Increase Odds of Bank of Canada Rate Hike</h2>
<p>On Friday, money markets significantly raised the likelihood of an interest rate increase by the Bank of Canada, now estimating over a 20% probability of a hike next month. This shift comes as the ongoing conflict in Iran continues without resolution and oil prices climb higher.</p>
<p>Previously, the overnight interest rate swap market had reflected only a minimal chance—about 4%—of a rate hike in April. However, new data from LSEG indicates that markets are now anticipating a total increase of 75 basis points in the central bank’s key policy rate by the end of the year. As of Thursday, traders had only expected a single 25 basis point rise in December.</p>
<p>This marks a dramatic reversal from earlier forecasts, which had leaned towards a potential rate cut.</p>

Money Markets Increase Odds of Bank of Canada Rate Hike On Friday, money markets significantly raised the likelihood of an interest rate increase by the Bank of Canada, now estimating over a 20% probability of a hike next month. This shift comes as the ongoing conflict in Iran continues without resolution and oil prices climb higher. Previously, the overnight interest rate swap market had reflected only a minimal chance—about 4%—of a rate hike in April. However, new data from LSEG indicates that markets are now anticipating a total increase of 75 basis points in the central bank’s key policy rate by the end of the year. As of Thursday, traders had only expected a single 25 basis point rise in December. This marks a dramatic reversal from earlier forecasts, which had leaned towards a potential rate cut.

Money markets increase expectations for a Bank of Canada rate hike in 2026 by 75 basis points

<div class="mt-5 wp-content "> 
 <p>Cardano (ADA) moves quietly between $0.18 and $0.25, a range that has often preceded spectacular rises. As crypto investors scrutinize the signals, one question remains… Does this silent accumulation herald an imminent breakout?</p> 
 <div class="thumbnail post-cover-image"> 
  <div> 
   <source>  
   <img src="https://img.bgstatic.com/spider-data/af9fedf1d407754defeaffc4c2006c901774030874001.jpg" class="post-cover-image--img">  
  </div> 
 </div> 
 <div class="in-brief"> 
  <div class="in-brief--container"> 
   <span class="in-brief--border-top"></span> 
   <span class="in-brief--border-bottom"></span> 
   <h2 class="in-brief--title">In brief</h2> 
   <div> 
    <ul> 
     <li>Cardano (ADA) consolidates between $0.18 and $0.25, a historic zone that has already triggered bull runs in the past.</li> 
     <li>A breakout above $0.25 could propel ADA towards $1, then $3.</li> 
     <li>Risks remain for Cardano: stubborn resistance, increased competition, and macroeconomic uncertainties.</li> 
    </ul> 
   </div> 
  </div> 
 </div> 
 <h2>Cardano in a phase of silent accumulation: what do the charts reveal?</h2> 
 <p>For several weeks, Cardano has been holding within a price range between $0.18 and $0.25. This range is significant because it has served as a springboard during previous bullish cycles, especially in 2023. Accordingly, the charts show progressive accumulation, with buying volumes increasing each time the price dips towards support.</p> 
 <div class="my-4"> 
  <div class="ads "> 
  </div> 
 </div> 
 <div>  
  <img width="1024" src="https://img.bgstatic.com/spider-data/ffb43fea0c30376f9935aceff308de981774030874315.webp" class="wp-image-935013">   
  <em>Cardano (ADA) accumulation zone.</em>  
 </div> 
 <p>Moreover, the RSI remains neutral while the 50- and 200-day moving averages begin to converge. This is a potential sign of preparation for a breakout. For crypto analysts, this phase of silent accumulation often precedes powerful bull runs. However, a breakout will only be confirmed with significant volume.</p> 
 <h2>Crypto: Cardano (ADA) at $1, then $3, is it realistic?</h2> 
 <p>If Cardano (ADA) manages to break the $0.25 resistance level with sufficient volume, price targets could shift quickly. The first target would be around $1, a major psychological level that would attract new buyers. Then, as seen in 2021, a breakout above $1.50 would open the way to $3. However, this scenario will depend on several factors:</p> 
 <ul> 
  <li>An overall bullish crypto market;</li> 
  <li>Increased adoption of Cardano;</li> 
  <li>Fundamental catalysts such as new partnerships or technological improvements.&nbsp;</li> 
 </ul> 
 <div class="affiliate-button"> 
 </div> 
 <h2>What strategies for Cardano investors in 2026?</h2> 
 <p>For short-term traders, the key levels to watch for ADA are $0.22 and $0.25. A breakout above $0.25 could provide a buying opportunity, while a drop below $0.18 would be a sell signal. In the medium term, a DCA (Dollar-Cost Averaging) strategy might be wise, smoothing risks while gradually accumulating ADA.</p> 
 <p>Additionally, crypto investors should also follow official Cardano announcements to anticipate potential catalysts. For the long term, holders can focus on Cardano’s fundamentals, such as its growing adoption and technological improvements. A 2-3 year vision could be rewarded if the project continues to develop.</p> 
 <div></div> 
 <p class="post-conclusion">Cardano stands at a decisive crossroads, between silent accumulation and explosive potential. If conditions align, a breakout could propel ADA to new heights. However, risks persist and crypto investors must remain cautious. What about you, do you think Cardano is ready for a new bull run?</p> 
 <div class="block-text-end-article"> 
  <p>Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.</p> 
  <br> 
  <div class="read-to-earn"> 
  </div> 
 </div> 
 <div class="mt-10"> 
  <div class="ads "> 
  </div> 
 </div> 
</div>

Cardano (ADA) moves quietly between $0.18 and $0.25, a range that has often preceded spectacular rises. As crypto investors scrutinize the signals, one question remains… Does this silent accumulation herald an imminent breakout? In brief Cardano (ADA) consolidates between $0.18 and $0.25, a historic zone that has already triggered bull runs in the past. A breakout above $0.25 could propel ADA towards $1, then $3. Risks remain for Cardano: stubborn resistance, increased competition, and macroeconomic uncertainties. Cardano in a phase of silent accumulation: what do the charts reveal? For several weeks, Cardano has been holding within a price range between $0.18 and $0.25. This range is significant because it has served as a springboard during previous bullish cycles, especially in 2023. Accordingly, the charts show progressive accumulation, with buying volumes increasing each time the price dips towards support. Cardano (ADA) accumulation zone. Moreover, the RSI remains neutral while the 50- and 200-day moving averages begin to converge. This is a potential sign of preparation for a breakout. For crypto analysts, this phase of silent accumulation often precedes powerful bull runs. However, a breakout will only be confirmed with significant volume. Crypto: Cardano (ADA) at $1, then $3, is it realistic? If Cardano (ADA) manages to break the $0.25 resistance level with sufficient volume, price targets could shift quickly. The first target would be around $1, a major psychological level that would attract new buyers. Then, as seen in 2021, a breakout above $1.50 would open the way to $3. However, this scenario will depend on several factors: An overall bullish crypto market; Increased adoption of Cardano; Fundamental catalysts such as new partnerships or technological improvements. What strategies for Cardano investors in 2026? For short-term traders, the key levels to watch for ADA are $0.22 and $0.25. A breakout above $0.25 could provide a buying opportunity, while a drop below $0.18 would be a sell signal. In the medium term, a DCA (Dollar-Cost Averaging) strategy might be wise, smoothing risks while gradually accumulating ADA. Additionally, crypto investors should also follow official Cardano announcements to anticipate potential catalysts. For the long term, holders can focus on Cardano’s fundamentals, such as its growing adoption and technological improvements. A 2-3 year vision could be rewarded if the project continues to develop. Cardano stands at a decisive crossroads, between silent accumulation and explosive potential. If conditions align, a breakout could propel ADA to new heights. However, risks persist and crypto investors must remain cautious. What about you, do you think Cardano is ready for a new bull run? Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Cardano at the dawn of a historic rally? What the data reveals

<h2>Quarterly Review: Therapeutics Sector Performance</h2>
<p>Quarterly earnings season offers a valuable opportunity to evaluate how companies are progressing, especially when compared to others in the therapeutics space. In this overview, we examine Moderna (NASDAQ:MRNA) alongside other top and bottom performers within the industry.</p>
<p>Therapeutics companies, which create a broad spectrum of treatments for various illnesses, are positioned to benefit in the coming years from advances in precision medicine—such as artificial intelligence enhancing drug discovery—and increasing demand for therapies addressing rare conditions. Nonetheless, the sector also faces challenges, including heightened scrutiny over drug costs, regulatory uncertainties, and stiff competition from larger pharmaceutical firms.</p>
<h3>Industry Snapshot</h3>
<p>Among the 11 therapeutics companies monitored, the fourth quarter was robust overall. Collectively, these firms surpassed Wall Street revenue forecasts by 7.1%.</p>
<p>Despite these positive results, share prices across the group have remained largely stable since the earnings announcements.</p>

<h2>Moderna (NASDAQ:MRNA)</h2>
<p>Moderna gained international recognition during the COVID-19 crisis by developing one of the earliest effective vaccines. The company specializes in messenger RNA (mRNA) therapies, which instruct the body’s cells to generate proteins that can treat or prevent a range of diseases.</p>
<p>For the quarter, Moderna posted $678 million in revenue, representing a 29.8% decline compared to the previous year. However, this figure still topped analyst projections by 2.7%. The company also exceeded expectations for both earnings per share and revenue, marking a standout quarter.</p>
<img src="https://img.bgstatic.com/spider-data/6725297d17d8c50de022c44beb390f821774030732098.jpeg" alt="Moderna Total Revenue">
<p>Despite recording the slowest revenue growth among its peers, Moderna’s stock has climbed 30.5% since the earnings release and is currently trading at $52.34.</p>

<h2>Top Q4 Performer: Novavax (NASDAQ:NVAX)</h2>
<p>Novavax is at the forefront of vaccine innovation, utilizing nanoparticle technology that imitates the structure of disease-causing agents. The company focuses on protein-based vaccines for infectious diseases, with its COVID-19 and combination respiratory vaccines leading its pipeline.</p>
<p>Novavax reported $147.1 million in revenue for the quarter, a 66.6% increase year-over-year and a remarkable 57.4% above analyst expectations. The company delivered a strong beat on both earnings and revenue estimates.</p>
<p>Novavax led the group with the highest revenue growth and the largest outperformance relative to analyst forecasts. The stock has risen 2.4% since the report and is now priced at $9.76.</p>

<h2>United Therapeutics (NASDAQ:UTHR)</h2>
<p>United Therapeutics was established by a mother seeking solutions for her child’s pulmonary arterial hypertension. The company develops and markets treatments for chronic lung diseases and other severe conditions, with a particular emphasis on pulmonary hypertension.</p>
<p>In the most recent quarter, United Therapeutics generated $790.2 million in revenue, a 7.4% year-over-year increase but 2.5% below analyst estimates. This quarter was softer for the company, as it missed revenue expectations by a notable margin.</p>
<p>Despite underperforming analyst forecasts more than any other peer, United Therapeutics’ shares have gained 11.3% since the results and currently trade at $527.05.</p>

<h2>Biogen (NASDAQ:BIIB)</h2>
<p>Founded in 1978, Biogen has been a pioneer in developing therapies for complex neurological disorders, including multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and rare conditions.</p>
<p>Biogen reported $2.28 billion in revenue for the quarter, up 1.2% from the previous year and 3.6% above analyst expectations. The company also delivered strong beats on both full-year earnings guidance and quarterly earnings per share.</p>
<p>The stock price has remained steady since the earnings announcement and is currently at $186.24.</p>

<h2>Gilead Sciences (NASDAQ:GILD)</h2>
<p>Gilead Sciences is renowned for its innovative treatments for life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. The company was instrumental in developing the first single-tablet HIV regimens.</p>
<p>For the quarter, Gilead posted $7.93 billion in revenue, a 4.7% year-over-year increase and 3.2% above analyst expectations. While the company outperformed on revenue, it slightly missed full-year earnings guidance.</p>
<p>Since the earnings release, Gilead’s stock has declined by 4% and is currently trading at $141.30.</p>

<h2>Market Trends and Shifts</h2>
<p>In late 2025 and early 2026, concerns about artificial intelligence began to weigh on the technology sector. Software companies worried that AI could undermine pricing power and reduce profit margins, while crypto investors feared that autonomous AI agents might diminish the value of existing crypto infrastructure.</p>
<p>These anxieties prompted investors to move away from riskier sectors in favor of safer assets. However, market sentiment shifted quickly in spring 2026, as attention turned from technological disruption to geopolitical tensions—particularly the US conflict with Iran. When geopolitical risks dominate, investors focus less on growth prospects and more on issues like oil supply, inflation, and global stability.</p>
<p><em>The StockStory analyst team, comprised of experienced professional investors, leverages quantitative analysis and automation to deliver high-quality, timely market insights.</em></p>

Quarterly Review: Therapeutics Sector Performance Quarterly earnings season offers a valuable opportunity to evaluate how companies are progressing, especially when compared to others in the therapeutics space. In this overview, we examine Moderna (NASDAQ:MRNA) alongside other top and bottom performers within the industry. Therapeutics companies, which create a broad spectrum of treatments for various illnesses, are positioned to benefit in the coming years from advances in precision medicine—such as artificial intelligence enhancing drug discovery—and increasing demand for therapies addressing rare conditions. Nonetheless, the sector also faces challenges, including heightened scrutiny over drug costs, regulatory uncertainties, and stiff competition from larger pharmaceutical firms. Industry Snapshot Among the 11 therapeutics companies monitored, the fourth quarter was robust overall. Collectively, these firms surpassed Wall Street revenue forecasts by 7.1%. Despite these positive results, share prices across the group have remained largely stable since the earnings announcements. Moderna (NASDAQ:MRNA) Moderna gained international recognition during the COVID-19 crisis by developing one of the earliest effective vaccines. The company specializes in messenger RNA (mRNA) therapies, which instruct the body’s cells to generate proteins that can treat or prevent a range of diseases. For the quarter, Moderna posted $678 million in revenue, representing a 29.8% decline compared to the previous year. However, this figure still topped analyst projections by 2.7%. The company also exceeded expectations for both earnings per share and revenue, marking a standout quarter. Despite recording the slowest revenue growth among its peers, Moderna’s stock has climbed 30.5% since the earnings release and is currently trading at $52.34. Top Q4 Performer: Novavax (NASDAQ:NVAX) Novavax is at the forefront of vaccine innovation, utilizing nanoparticle technology that imitates the structure of disease-causing agents. The company focuses on protein-based vaccines for infectious diseases, with its COVID-19 and combination respiratory vaccines leading its pipeline. Novavax reported $147.1 million in revenue for the quarter, a 66.6% increase year-over-year and a remarkable 57.4% above analyst expectations. The company delivered a strong beat on both earnings and revenue estimates. Novavax led the group with the highest revenue growth and the largest outperformance relative to analyst forecasts. The stock has risen 2.4% since the report and is now priced at $9.76. United Therapeutics (NASDAQ:UTHR) United Therapeutics was established by a mother seeking solutions for her child’s pulmonary arterial hypertension. The company develops and markets treatments for chronic lung diseases and other severe conditions, with a particular emphasis on pulmonary hypertension. In the most recent quarter, United Therapeutics generated $790.2 million in revenue, a 7.4% year-over-year increase but 2.5% below analyst estimates. This quarter was softer for the company, as it missed revenue expectations by a notable margin. Despite underperforming analyst forecasts more than any other peer, United Therapeutics’ shares have gained 11.3% since the results and currently trade at $527.05. Biogen (NASDAQ:BIIB) Founded in 1978, Biogen has been a pioneer in developing therapies for complex neurological disorders, including multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and rare conditions. Biogen reported $2.28 billion in revenue for the quarter, up 1.2% from the previous year and 3.6% above analyst expectations. The company also delivered strong beats on both full-year earnings guidance and quarterly earnings per share. The stock price has remained steady since the earnings announcement and is currently at $186.24. Gilead Sciences (NASDAQ:GILD) Gilead Sciences is renowned for its innovative treatments for life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. The company was instrumental in developing the first single-tablet HIV regimens. For the quarter, Gilead posted $7.93 billion in revenue, a 4.7% year-over-year increase and 3.2% above analyst expectations. While the company outperformed on revenue, it slightly missed full-year earnings guidance. Since the earnings release, Gilead’s stock has declined by 4% and is currently trading at $141.30. Market Trends and Shifts In late 2025 and early 2026, concerns about artificial intelligence began to weigh on the technology sector. Software companies worried that AI could undermine pricing power and reduce profit margins, while crypto investors feared that autonomous AI agents might diminish the value of existing crypto infrastructure. These anxieties prompted investors to move away from riskier sectors in favor of safer assets. However, market sentiment shifted quickly in spring 2026, as attention turned from technological disruption to geopolitical tensions—particularly the US conflict with Iran. When geopolitical risks dominate, investors focus less on growth prospects and more on issues like oil supply, inflation, and global stability. The StockStory analyst team, comprised of experienced professional investors, leverages quantitative analysis and automation to deliver high-quality, timely market insights.

Therapeutics Stocks Q4 Analysis: Comparing Moderna (NASDAQ:MRNA) With Its Peers

<div> 
 <p><span style="font-weight: 400">Ethereum investor Stanley Druckenmiller has added his voice to the growing conversation around the </span><span style="font-weight: 400">future</span><span style="font-weight: 400"> of digital finance, predicting that stablecoins could become the dominant force in global payment systems within the next few years. The veteran investor’s outlook reflects a broader shift among institutions and market participants toward viewing blockchain-based money as a critical financial infrastructure.</span></p> 
 <h2 class="ftwp-heading">Why Stablecoins Could Replace Traditional Payment Rails</h2> 
 <p><span style="font-weight: 400">Stanley Druckenmiller, a prominent investor with </span><span style="font-weight: 400">exposure</span><span style="font-weight: 400"> to Ethereum, is increasingly aligning his investment positioning with his outlook on the future of payments; one dominated by stablecoins and blockchain infrastructure. According to the Etherealize </span><span style="font-weight: 400">post</span><span style="font-weight: 400"> on X, the veteran investor has publicly stated that stablecoins could power the entire payment system within the next 10 to 15 years. He further pointed to the clear advantages of blockchain-based money, such as greater efficiency, faster settlement, and significantly lower costs.</span></p> 
 <div class="jeg_block_heading jeg_block_heading_6 related-news-title__related-news"> 
  <h2 class="jeg_block_title"><span>Related Reading</span></h2> 
 </div> 
 <div class="related-reading__row"> 
  <div> 
   <div class="block-article__link"> 
    <div class="block-article__figure-container">  
     <span class="pageable-container"> <img width="540" src="https://img.bgstatic.com/spider-data/05e23464ba9bc885a1edb7e9440b443a1774030726703.jpg" class="block-article__image"> </span>  
    </div> 
    <div class="block-article__content"> 
      <h4 class="block-article__title"> Ethereum Investor Druckenmiller Predicts Stablecoin-Led Payment Systems</h4> 
     <span class="block-article__author"> 18 minutes ago</span> 
    </div>  
   </div> 
  </div> 
 </div> 
 <p><span style="font-weight: 400">This view is reflected in his exposure of the ETH ecosystem, in which Druckenmiller is listed among key backers of</span><span style="font-weight: 400"> BitMine</span><span style="font-weight: 400"> (BMNR), an Ethereum-focused treasury firm chaired by Tom Lee, which reportedly holds over $10 billion in ETH. Other notable supporters include ARK Invest and Bill Miller.</span></p> 
 <div class="jeg_ad jeg_ad_article jnews_content_inline_ads  "> 
  <div class="ads-wrapper align-center "> 
   <div class="ads_shortcode"> 
    <div class="jeg_ad jeg_ad_article"> 
     <div class="ads-wrapper align-center"> 
      <div class="ads_code">  var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607465 = window.pid607465 || rnd; var plc607465 = window.plc607465 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607465;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607465+';place='+(plc607465++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' 
       <div></div>'); 
      </div> 
     </div> 
    </div> 
    <div class="jeg_ad jeg_ad_article"> 
     <div class="ads-wrapper align-center"> 
      <div class="ads_code">  if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = "https://servedbyadbutler.com/app.js";var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} 
       <div class="plc366606"></div> var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ""; var plc366606 = window.plc366606 || 0; (function(){ var divs = document.querySelectorAll(".plc366606:not([id])"); var div = divs[divs.length-1]; div.id = "placement_366606_"+plc366606; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 366606, [728,90], "placement_366606_"+opt.place, opt); }, opt: { place: plc366606++, keywords: abkw, domain: "servedbyadbutler.com", click:"CLICK_MACRO_PLACEHOLDER" }}); })(); 
      </div> 
     </div> 
    </div> 
   </div> 
  </div> 
 </div> 
 <p><span style="font-weight: 400">Druckenmiller’s aligns with his recent bullish comments on stablecoins and blockchain payments. He frames blockchain and the use of stablecoins as highly practical tools for investors to invest their crypto and tokens, as they can significantly improve financial productivity.</span></p> 
 <h2 class="ftwp-heading">Ethereum As A Neutral Settlement Layer For Institutions</h2> 
 <p><span style="font-weight: 400">The recent Cari </span><span style="font-weight: 400">announcement</span><span style="font-weight: 400"> has reignited a critical debate around the future of institutional blockchain infrastructure, with much of the discussion focusing on architecture. Analyst Alex </span><span style="font-weight: 400">argued</span><span style="font-weight: 400"> that the real issue lies in the business model of proprietary systems versus open standards.</span></p> 
 <div class="jeg_block_heading jeg_block_heading_6 related-news-title__related-news"> 
  <h2 class="jeg_block_title"><span>Related Reading</span></h2> 
 </div> 
 <div class="related-reading__row"> 
  <div> 
   <div class="block-article__link"> 
    <div class="block-article__figure-container">  
     <span class="pageable-container"> <img width="860" src="https://img.bgstatic.com/spider-data/c0427083620d61a99f4c08faa6b6bf081774030727085.jpg" class="block-article__image"> </span>  
    </div> 
    <div class="block-article__content"> 
      <h4 class="block-article__title"> Ethereum Futures Volume Outruns Spot 6-to-1 As Macro Stress Weighs On Crypto</h4> 
     <span class="block-article__author"> 3 days ago</span> 
    </div>  
   </div> 
  </div> 
 </div> 
 <p><span style="font-weight: 400">The Government of propriety networks like Canton or Tempo will be controlled by a small group with disproportionate voting weight. They will be permissionless, but participants have to submit a Google </span><span style="font-weight: 400">form</span><span style="font-weight: 400"> with opaque admission criteria to join. It’s unclear who decides this, but over time, the most influential participants will set the terms of access and pricing.</span></p> 
 <div class="jeg_ad jeg_ad_article jnews_content_inline_2_ads  "> 
  <div class="ads-wrapper align-center "> 
   <div class="ads_shortcode"> 
    <div class="jeg_ad jeg_ad_article"> 
     <div class="ads-wrapper align-center"> 
      <div class="ads_code">  var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607472 = window.pid607472 || rnd; var plc607472 = window.plc607472 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607472;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607472+';place='+(plc607472++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' 
       <div></div>'); 
      </div> 
     </div> 
    </div> 
    <div class="jeg_ad jeg_ad_article"> 
     <div class="ads-wrapper align-center"> 
      <div class="ads_code">  if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = "https://servedbyadbutler.com/app.js";var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} 
       <div class="plc452518"></div> var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ""; var plc452518 = window.plc452518 || 0; (function(){ var divs = document.querySelectorAll(".plc452518:not([id])"); var div = divs[divs.length-1]; div.id = "placement_452518_"+plc452518; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 452518, [728,90], "placement_452518_"+opt.place, opt); }, opt: { place: plc452518++, keywords: abkw, domain: "servedbyadbutler.com", click:"CLICK_MACRO_PLACEHOLDER" }}); })(); 
      </div> 
     </div> 
    </div> 
   </div> 
  </div> 
 </div> 
 <p><span style="font-weight: 400">From a bank’s perspective, this structure is familiar because it mirrors the early dynamics of legacy systems like SWIFT and Visa, locking in structural advantages while late joiners absorb the cost.&nbsp;</span></p> 
 <p><span style="font-weight: 400">As Alex noted, everyone wants to build the next SWIFT-killer, but nobody wants to join someone else’s SWIFT-Killer; a typical comment from banks. This is where Ethereum stands out as the only neutral settlement layer where that dynamic can’t take hold, because no single entity can capture it.&nbsp;</span></p> 
 <p><span style="font-weight: 400">The </span><span style="font-weight: 400">ETH network</span><span style="font-weight: 400"> is the only place where every participant can permanently trust that no future coalition will rewrite the rules against them. From a game-theoretical standpoint, Alex concluded that ETH represents the only sustainable equilibrium as a global settlement layer for institutional finance that works </span><span style="font-weight: 400">long-term</span><span style="font-weight: 400">.</span></p> 
 <div class="jeg_ad jeg_ad_article jnews_content_inline_3_ads  "> 
  <div class="ads-wrapper align-center "> 
   <div class="ads_shortcode"> 
    <div class="jeg_ad jeg_ad_article"> 
     <div class="ads-wrapper align-center"> 
      <div class="ads_code">  var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607473 = window.pid607473 || rnd; var plc607473 = window.plc607473 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607473;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607473+';place='+(plc607473++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' 
       <div></div>'); 
      </div> 
     </div> 
    </div> 
    <div class="jeg_ad jeg_ad_article"> 
     <div class="ads-wrapper align-center"> 
      <div class="ads_code">  if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = 'https://servedbyadbutler.com/app.js';var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} 
       <div class="plc452519"></div> var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ''; var plc452519 = window.plc452519 || 0; (function(){ var divs = document.querySelectorAll(".plc452519:not([id])"); var div = divs[divs.length-1]; div.id = "placement_452519_"+plc452519; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 452519, [728,90], 'placement_452519_'+opt.place, opt); }, opt: { place: plc452519++, keywords: abkw, domain: 'servedbyadbutler.com', click:'CLICK_MACRO_PLACEHOLDER' }}); })(); 
      </div> 
     </div> 
    </div> 
   </div> 
  </div> 
 </div> 
 <div> 
  <img class="size-large" src="https://img.bgstatic.com/spider-data/e598b87fa469e09cd930bddc054f3d1d1774030727281.jpeg" width="2084">  ETH trading at $2,150 on the 1D chart | Source: ETHUSDT on 
   Tradingview.com 
 </div> 
</div>

Ethereum investor Stanley Druckenmiller has added his voice to the growing conversation around the future of digital finance, predicting that stablecoins could become the dominant force in global payment systems within the next few years. The veteran investor’s outlook reflects a broader shift among institutions and market participants toward viewing blockchain-based money as a critical financial infrastructure. Why Stablecoins Could Replace Traditional Payment Rails Stanley Druckenmiller, a prominent investor with exposure to Ethereum, is increasingly aligning his investment positioning with his outlook on the future of payments; one dominated by stablecoins and blockchain infrastructure. According to the Etherealize post on X, the veteran investor has publicly stated that stablecoins could power the entire payment system within the next 10 to 15 years. He further pointed to the clear advantages of blockchain-based money, such as greater efficiency, faster settlement, and significantly lower costs. Related Reading Ethereum Investor Druckenmiller Predicts Stablecoin-Led Payment Systems 18 minutes ago This view is reflected in his exposure of the ETH ecosystem, in which Druckenmiller is listed among key backers of BitMine (BMNR), an Ethereum-focused treasury firm chaired by Tom Lee, which reportedly holds over $10 billion in ETH. Other notable supporters include ARK Invest and Bill Miller. var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607465 = window.pid607465 || rnd; var plc607465 = window.plc607465 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607465;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607465+';place='+(plc607465++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' '); if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = "https://servedbyadbutler.com/app.js";var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ""; var plc366606 = window.plc366606 || 0; (function(){ var divs = document.querySelectorAll(".plc366606:not([id])"); var div = divs[divs.length-1]; div.id = "placement_366606_"+plc366606; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 366606, [728,90], "placement_366606_"+opt.place, opt); }, opt: { place: plc366606++, keywords: abkw, domain: "servedbyadbutler.com", click:"CLICK_MACRO_PLACEHOLDER" }}); })(); Druckenmiller’s aligns with his recent bullish comments on stablecoins and blockchain payments. He frames blockchain and the use of stablecoins as highly practical tools for investors to invest their crypto and tokens, as they can significantly improve financial productivity. Ethereum As A Neutral Settlement Layer For Institutions The recent Cari announcement has reignited a critical debate around the future of institutional blockchain infrastructure, with much of the discussion focusing on architecture. Analyst Alex argued that the real issue lies in the business model of proprietary systems versus open standards. Related Reading Ethereum Futures Volume Outruns Spot 6-to-1 As Macro Stress Weighs On Crypto 3 days ago The Government of propriety networks like Canton or Tempo will be controlled by a small group with disproportionate voting weight. They will be permissionless, but participants have to submit a Google form with opaque admission criteria to join. It’s unclear who decides this, but over time, the most influential participants will set the terms of access and pricing. var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607472 = window.pid607472 || rnd; var plc607472 = window.plc607472 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607472;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607472+';place='+(plc607472++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' '); if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = "https://servedbyadbutler.com/app.js";var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ""; var plc452518 = window.plc452518 || 0; (function(){ var divs = document.querySelectorAll(".plc452518:not([id])"); var div = divs[divs.length-1]; div.id = "placement_452518_"+plc452518; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 452518, [728,90], "placement_452518_"+opt.place, opt); }, opt: { place: plc452518++, keywords: abkw, domain: "servedbyadbutler.com", click:"CLICK_MACRO_PLACEHOLDER" }}); })(); From a bank’s perspective, this structure is familiar because it mirrors the early dynamics of legacy systems like SWIFT and Visa, locking in structural advantages while late joiners absorb the cost. As Alex noted, everyone wants to build the next SWIFT-killer, but nobody wants to join someone else’s SWIFT-Killer; a typical comment from banks. This is where Ethereum stands out as the only neutral settlement layer where that dynamic can’t take hold, because no single entity can capture it. The ETH network is the only place where every participant can permanently trust that no future coalition will rewrite the rules against them. From a game-theoretical standpoint, Alex concluded that ETH represents the only sustainable equilibrium as a global settlement layer for institutional finance that works long-term. var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607473 = window.pid607473 || rnd; var plc607473 = window.plc607473 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607473;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607473+';place='+(plc607473++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' '); if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = 'https://servedbyadbutler.com/app.js';var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ''; var plc452519 = window.plc452519 || 0; (function(){ var divs = document.querySelectorAll(".plc452519:not([id])"); var div = divs[divs.length-1]; div.id = "placement_452519_"+plc452519; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 452519, [728,90], 'placement_452519_'+opt.place, opt); }, opt: { place: plc452519++, keywords: abkw, domain: 'servedbyadbutler.com', click:'CLICK_MACRO_PLACEHOLDER' }}); })(); ETH trading at $2,150 on the 1D chart | Source: ETHUSDT on Tradingview.com

Ethereum Investor Druckenmiller Predicts Stablecoin-Led Payment Systems

<div class="post-detail__content blocks"> 
 <p class="is-style-lead">Bhutan has sold over $110m in Bitcoin in 2026, cutting sovereign holdings by about 65% from their peak as Druk Holding shifts from mining-led accumulation to steady liquidation.</p> 
 <div class="cn-block-summary"> 
  <div class="cn-block-summary__nav tabs"> 
   <span class="tabs__item is-selected">Summary</span> 
  </div> 
  <div class="cn-block-summary__content"> 
   <ul class="wp-block-list"> 
    <li>Druk Holding &amp; Investments has offloaded more than $110m in BTC this year, including a 973 BTC transfer worth about $72.3m on March 17–18 routed partly through QCP Capital and Binance.</li> 
    <li>Bhutan’s stash has shrunk from roughly 13,000 BTC (over $1.4b and 40% of GDP at peak) to around 5,400 BTC worth about $374m, with no inflows over $100k in more than a year, implying mining has largely stopped.</li> 
    <li>The kingdom’s methodical $5–10m clip sales, built on hydropower-funded mining since 2019, now act as a recurring sovereign overhang for Bitcoin just as macro conditions and sentiment remain fragile.</li> 
   </ul> 
  </div> 
 </div>  
 <p>The Kingdom of Bhutan has quietly become one of the most closely watched sovereign Bitcoin sellers of 2026, with its state investment arm offloading more than $110 million worth of BTC since the start of the year — a systematic drawdown that has cut its holdings by 65% from their peak and raised questions about the future of one of crypto’s most unlikely national success stories.</p> 
 <p>The latest and largest transaction occurred on March 17 and 18, when Druk Holding &amp; Investments — the sovereign wealth fund that manages Bhutan’s digital asset reserves — transferred 973 BTC worth approximately $72.3 million across multiple addresses. Among the recipients was QCP Capital, a Singapore-based institutional trading firm, indicating structured OTC selling designed to minimize market impact rather than distressed dumping onto open exchanges. A portion was also directed toward Binance hot wallets.</p>  
 <p>Bhutan’s Bitcoin journey began in 2019, when the country began quietly mining BTC using surplus hydroelectric power from its Himalayan rivers — a near-zero marginal cost energy source that made mining highly profitable even at modest price levels. At its peak, Bhutan held approximately 13,000 BTC, valued at over $1.4 billion — a sum representing more than 40% of the country’s entire gross domestic product at the time. Those holdings have since contracted to roughly 5,400 BTC, worth around $374 million at current prices.</p> 
 <p>A critical detail flagged by on-chain analytics firm Arkham Intelligence adds a new dimension to the story: Bhutan has not recorded a Bitcoin inflow of over $100,000 in more than a year. This strongly suggests the country has halted or severely curtailed its mining operations, shifting from an accumulation-and-hold strategy to a pure liquidation mode. The reasons remain officially unconfirmed, but analysts have pointed to declining mining profitability following the April 2024 halving, rising operational costs, and competing demands on the country’s hydropower infrastructure.</p> 
 <p>The selling pattern has been methodical rather than reactive. Bhutan typically transacts in $5–10 million clips, with occasional larger tranches when market conditions are favorable. The $72.3 million move this week is an outlier in size, suggesting either an acceleration of the drawdown timeline or an opportunistic decision to lock in prices near the $71,000 level before further deterioration.</p> 
 <p>For the broader market, the sustained presence of sovereign-scale selling at these volumes is a non-trivial headwind. Unlike retail or even institutional fund selling, sovereign liquidations tend to be price-insensitive and recurring — features that can create persistent ceiling pressure on any attempted recovery. As Bitcoin navigates a fragile macro environment with fear sentiment elevated and ETF flows recently reversing, Bhutan’s quiet but relentless selling is one more structural force the bulls must absorb on the path back to new highs.</p>  
</div>

Bhutan has sold over $110m in Bitcoin in 2026, cutting sovereign holdings by about 65% from their peak as Druk Holding shifts from mining-led accumulation to steady liquidation. Summary Druk Holding & Investments has offloaded more than $110m in BTC this year, including a 973 BTC transfer worth about $72.3m on March 17–18 routed partly through QCP Capital and Binance. Bhutan’s stash has shrunk from roughly 13,000 BTC (over $1.4b and 40% of GDP at peak) to around 5,400 BTC worth about $374m, with no inflows over $100k in more than a year, implying mining has largely stopped. The kingdom’s methodical $5–10m clip sales, built on hydropower-funded mining since 2019, now act as a recurring sovereign overhang for Bitcoin just as macro conditions and sentiment remain fragile. The Kingdom of Bhutan has quietly become one of the most closely watched sovereign Bitcoin sellers of 2026, with its state investment arm offloading more than $110 million worth of BTC since the start of the year — a systematic drawdown that has cut its holdings by 65% from their peak and raised questions about the future of one of crypto’s most unlikely national success stories. The latest and largest transaction occurred on March 17 and 18, when Druk Holding & Investments — the sovereign wealth fund that manages Bhutan’s digital asset reserves — transferred 973 BTC worth approximately $72.3 million across multiple addresses. Among the recipients was QCP Capital, a Singapore-based institutional trading firm, indicating structured OTC selling designed to minimize market impact rather than distressed dumping onto open exchanges. A portion was also directed toward Binance hot wallets. Bhutan’s Bitcoin journey began in 2019, when the country began quietly mining BTC using surplus hydroelectric power from its Himalayan rivers — a near-zero marginal cost energy source that made mining highly profitable even at modest price levels. At its peak, Bhutan held approximately 13,000 BTC, valued at over $1.4 billion — a sum representing more than 40% of the country’s entire gross domestic product at the time. Those holdings have since contracted to roughly 5,400 BTC, worth around $374 million at current prices. A critical detail flagged by on-chain analytics firm Arkham Intelligence adds a new dimension to the story: Bhutan has not recorded a Bitcoin inflow of over $100,000 in more than a year. This strongly suggests the country has halted or severely curtailed its mining operations, shifting from an accumulation-and-hold strategy to a pure liquidation mode. The reasons remain officially unconfirmed, but analysts have pointed to declining mining profitability following the April 2024 halving, rising operational costs, and competing demands on the country’s hydropower infrastructure. The selling pattern has been methodical rather than reactive. Bhutan typically transacts in $5–10 million clips, with occasional larger tranches when market conditions are favorable. The $72.3 million move this week is an outlier in size, suggesting either an acceleration of the drawdown timeline or an opportunistic decision to lock in prices near the $71,000 level before further deterioration. For the broader market, the sustained presence of sovereign-scale selling at these volumes is a non-trivial headwind. Unlike retail or even institutional fund selling, sovereign liquidations tend to be price-insensitive and recurring — features that can create persistent ceiling pressure on any attempted recovery. As Bitcoin navigates a fragile macro environment with fear sentiment elevated and ETF flows recently reversing, Bhutan’s quiet but relentless selling is one more structural force the bulls must absorb on the path back to new highs.

 Bhutan has sold over $110m in Bitcoin as sovereign stack drops 65% 

<span class="ast-_PPhhqv6"><span>Looking at a rebound here back to 387-390...</span><br><span>Or channel top .</span><br><br><span>Stop loss below 366.. </span><br><span>Has a gap to close at 368 from Sept 2025.</span><br><br><span>4hr and daily candle outside Bbands, this is not sustainable </span></span>

Looking at a rebound here back to 387-390... Or channel top . Stop loss below 366.. Has a gap to close at 368 from Sept 2025. 4hr and daily candle outside Bbands, this is not sustainable

Tsla

<span class="ast-_PPhhqv6"><br><span>— Test of the lower consolidation zone, possible formation of a triangle pattern with targets of a new high</span><br><br><span>— Entry: $178 – market buy order</span><br><span>— Stop: $170</span><br><span>— Target: $210</span><br><br><span>Risk per trade: 0.2% of total deposit</span><br><br><span>Position size: 5% of total deposit</span><br><br><span>RR 1:4.8</span><br></span>

— Test of the lower consolidation zone, possible formation of a triangle pattern with targets of a new high — Entry: $178 – market buy order — Stop: $170 — Target: $210 Risk per trade: 0.2% of total deposit Position size: 5% of total deposit RR 1:4.8

NVIDIA/USD Long Trade Idea TradFi 

<span class="ast-_PPhhqv6"><span>20.MAR.2026 : MICROSFT on support zone , stock loss 30% , in my view point this deal is risk free , because its microsoft , no need to thinking twice , be patient </span><br><br><span>entry : 389</span><br><span>target : 533</span><br><br><span>good luck ,,, </span></span>

20.MAR.2026 : MICROSFT on support zone , stock loss 30% , in my view point this deal is risk free , because its microsoft , no need to thinking twice , be patient entry : 389 target : 533 good luck ,,,

MICROSOFT LOSS 30%

<div class="post-article-content  lg:col-span-5  px-2  lg:px-6"> 
 <div class="-mt-16  mb-8  lg:-mt-20  rounded-md  shadow-md"> 
  <div class="relative  z-10  post-article-image  rounded  overflow-hidden"> 
   <div> 
    <source type="image/webp"> 
    <source type="image/webp"> 
    <source type="image/jpeg"> 
    <source type="image/jpeg"> 
    <img src="https://img.bgstatic.com/spider-data/746c266937b50ab5c5bbea12cf169c601774030513975.png" width="100%"> 
   </div> 
  </div> 
 </div> 
 <ul> 
  <li><span style="font-weight: 400;">Stellar price hovered near $0.16 as bulls looked for a bounce despite the recent sell-off.</span></li> 
  <li><span style="font-weight: 400;">XLM is among the coins designated as digital commodities under SEC and CFTC interpretations.</span></li> 
  <li><span style="font-weight: 400;">€2.3 trillion asset manager Amundi launched a $100 million tokenized fund on Stellar.</span></li> 
 </ul> 
 <p>Stellar Lumens (XLM) trades near $0.16 as bulls eye a rebound to month-to-date highs following recent sell-off.</p> 
 <p>Could this outlook materialize amid renewed investor attention on Stellar, with multiple potential catalysts in place? Developments across the ecosystem suggest so, and immediate targets include the psychological $0.20 mark.</p> 
 <h2>Stellar gets key boost alongside Ethereum</h2> 
 <p>The XLM token has pared recent gains to $0.18, and market data shows bulls are 41% down since touching highs of $0.50 in July 2025.</p> 
 <p>An overall downtrend puts bulls at risk of new pain.</p> 
 <p>However, the Stellar blockchain network is headlining crypto market sentiment amid a significant regulatory tailwind.</p> 
 <p>A Europe-based asset manager has also shown confidence in Stellar.</p> 
 <p>On the regulatory front, XLM is among several coins to receive official designation as digital commodities.</p> 
 <p>This follows a joint interpretation by the US SEC and CFTC, which listed XLM among other coins as digital commodities.</p> 
 <p>This clarity positions XLM favorably for compliant institutional adoption, reducing longstanding uncertainties that have hindered growth.</p> 
 <p>Elsewhere, Europe’s €2.3 trillion asset manager Amundi launched a $100 million tokenized fund on both Stellar and Ethereum networks.</p> 
 <p>The move reinforces the altcoin project’s potential in real-world asset tokenization.</p> 
 <p><span style="font-weight: 400;">On top of this news, on-chain data shows Stellar had a robust Q4, 2025. </span></p> 
 <p><span style="font-weight: 400;">The real-world asset (RWA) market cap </span><span style="font-weight: 400;">grew </span><span style="font-weight: 400;">196% year-over-year to more than $890 million, and the stablecoin market cap jumped 53% to $243 million.</span></p> 
 <p><span style="font-weight: 400;">The other notable developments are a spike in DeFi TVL as a major US bank teased a stablecoin issuance on Stellar.</span></p> 
 <p>These ecosystem advancements highlight Stellar’s expanding role in bridging traditional finance and blockchain.</p> 
 <h2>XLM price forecast: is $0.20 next?</h2> 
 <p>Stellar price paints a bullish picture on the daily chart, with the decrease in intraday volume suggesting waning selling pressure.</p> 
 <p><span style="font-weight: 400;">According to data from CoinMarketCap, daily trading volume was down 16% in the past 24 hours to around $88 million.</span></p> 
 <p>Meanwhile, daily RSI reflects a neutral-to-bullish stance, hovering near 54 to indicate ample upside potential before overbought conditions.</p> 
 <p>The divergence suggests buyers are regaining control after recent consolidations around below $0.17.</p> 
 <div> 
  <img class="size-full wp-image-363659" src="https://img.bgstatic.com/spider-data/1bc7d724fde85fc7b6dd5dda1dfd75e81774030514417.png" width="1057">  
  Stellar XLM price chart by TradingView  
 </div> 
 <p>If prices move higher, a breakout to $0.20 could allow bulls to revisit the 0.236 Fibonacci retracement level at $0.22.</p> 
 <p>More gains and bulls could eye $0.32 (aligns with the 0.5 Fibonacci retracement level).</p> 
 <p>However, downside risks include a drop in Bitcoin prices. XLM below $0.16 risks bearish continuation $0.13 or lower.</p> 
 <div class="post-meta"> 
  <div></div> 
  <h6 class="text-3xl  mb-4  text-green-300">Share this article</h6> 
  <div class="share  mb-6  mx-6  md:mx-0"> 
   <div class="flex  flex-wrap  -ml-3  font-bold  text-xxs  text-center  uppercase"> 
      
    </div> 
  </div> 
  <div></div> 
  <h6 class="text-3xl  mb-4  text-green-300">Categories</h6> 
  <div class="tags  mx-6  md:mx-0"> 
   <div class="flex  flex-wrap  -ml-3  mb-4  lg:mb-6  font-bold  text-xxs  text-center  uppercase"> 
    <div class="pl-3  mb-3"> 
     <a href="https://coinjournal.net/news/category/markets/" class="block  py-2.5  px-2  bg-grey-100  leading-[0.45rem]  transition-colors  hover:bg-grey-300">Markets</a> 
    </div> 
   </div> 
  </div> 
  <div></div> 
  <h6 class="text-3xl  mb-4  text-green-300">Tags</h6> 
  <div class="tags  mx-6  md:mx-0"> 
   <div class="flex  flex-wrap  -ml-3  mb-4  lg:mb-6  font-bold  text-xxs  text-center  uppercase"> 
    <div class="pl-3  mb-3"> 
     <a href="https://coinjournal.net/news/tag/xlm/" class="block  py-2.5  px-2  bg-grey-100  leading-[0.45rem]  transition-colors  hover:bg-grey-300">XLM News</a> 
    </div> 
   </div> 
  </div> 
 </div> 
</div>

Stellar price hovered near $0.16 as bulls looked for a bounce despite the recent sell-off. XLM is among the coins designated as digital commodities under SEC and CFTC interpretations. €2.3 trillion asset manager Amundi launched a $100 million tokenized fund on Stellar. Stellar Lumens (XLM) trades near $0.16 as bulls eye a rebound to month-to-date highs following recent sell-off. Could this outlook materialize amid renewed investor attention on Stellar, with multiple potential catalysts in place? Developments across the ecosystem suggest so, and immediate targets include the psychological $0.20 mark. Stellar gets key boost alongside Ethereum The XLM token has pared recent gains to $0.18, and market data shows bulls are 41% down since touching highs of $0.50 in July 2025. An overall downtrend puts bulls at risk of new pain. However, the Stellar blockchain network is headlining crypto market sentiment amid a significant regulatory tailwind. A Europe-based asset manager has also shown confidence in Stellar. On the regulatory front, XLM is among several coins to receive official designation as digital commodities. This follows a joint interpretation by the US SEC and CFTC, which listed XLM among other coins as digital commodities. This clarity positions XLM favorably for compliant institutional adoption, reducing longstanding uncertainties that have hindered growth. Elsewhere, Europe’s €2.3 trillion asset manager Amundi launched a $100 million tokenized fund on both Stellar and Ethereum networks. The move reinforces the altcoin project’s potential in real-world asset tokenization. On top of this news, on-chain data shows Stellar had a robust Q4, 2025. The real-world asset (RWA) market cap grew 196% year-over-year to more than $890 million, and the stablecoin market cap jumped 53% to $243 million. The other notable developments are a spike in DeFi TVL as a major US bank teased a stablecoin issuance on Stellar. These ecosystem advancements highlight Stellar’s expanding role in bridging traditional finance and blockchain. XLM price forecast: is $0.20 next? Stellar price paints a bullish picture on the daily chart, with the decrease in intraday volume suggesting waning selling pressure. According to data from CoinMarketCap, daily trading volume was down 16% in the past 24 hours to around $88 million. Meanwhile, daily RSI reflects a neutral-to-bullish stance, hovering near 54 to indicate ample upside potential before overbought conditions. The divergence suggests buyers are regaining control after recent consolidations around below $0.17. Stellar XLM price chart by TradingView If prices move higher, a breakout to $0.20 could allow bulls to revisit the 0.236 Fibonacci retracement level at $0.22. More gains and bulls could eye $0.32 (aligns with the 0.5 Fibonacci retracement level). However, downside risks include a drop in Bitcoin prices. XLM below $0.16 risks bearish continuation $0.13 or lower. Share this article Categories Markets Tags XLM News

XLM price forecast: is $0.20 next amid confluence of bullish factors?

<h2>Integral Health Asset Management Increases Vera Therapeutics Stake</h2>
<p>On February 17, 2026, Integral Health Asset Management reported the purchase of 100,000 shares of <strong>Vera Therapeutics</strong> (<span class="ticker">NASDAQ:VERA</span>), a transaction valued at approximately $3.55 million based on the average price for the previous quarter.</p>

<h3>Details of the Transaction</h3>
<p>As outlined in a SEC filing dated February 17, 2026, Integral Health Asset Management expanded its position in Vera Therapeutics by an additional 100,000 shares. This acquisition, calculated using the average closing price for the quarter ending December 31, 2025, is estimated at $3.55 million. The total value of the holding increased by $41.75 million, reflecting both new share purchases and changes in Vera’s stock price.</p>

<h3>Key Takeaways</h3>
<ul>
  <li>Following this transaction, Vera Therapeutics now represents 4.53% of the fund’s 13F assets under management.</li>
  <li>
    <strong>Top portfolio holdings after this filing include:</strong>
    <ul>
      <li>NASDAQ:INSM – $217.55 million (11.0% of AUM)</li>
      <li>NASDAQ:RVMD – $95.58 million (4.8% of AUM)</li>
      <li>NASDAQ:VERA – $91.15 million (4.5% of AUM)</li>
      <li>NASDAQ:CYTK – $88.96 million (4.5% of AUM)</li>
      <li>NASDAQ:REGN – $81.05 million (4.1% of AUM)</li>
    </ul>
  </li>
  <li>As of the most recent Friday, Vera Therapeutics shares closed at $40.93, marking a 48% increase over the past year—significantly outperforming the S&amp;P 500’s approximate 16% gain during the same period.</li>
</ul>

<h3>Vera Therapeutics: Company Overview</h3>
<table>
  <tbody>
    <tr>
      <td><strong>Market Capitalization</strong></td>
      <td>$2.9 billion</td>
    </tr>
    <tr>
      <td><strong>Share Price (as of Friday)</strong></td>
      <td>$40.93</td>
    </tr>
    <tr>
      <td><strong>Net Income (TTM)</strong></td>
      <td>($299.6 million)</td>
    </tr>
  </tbody>
</table>

<h3>About Vera Therapeutics</h3>
<ul>
  <li>Vera Therapeutics is dedicated to developing and bringing to market therapies for severe immune-related conditions. Its main drug candidates include atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia.</li>
  <li>The company operates as a clinical-stage biotech firm, focusing on advancing proprietary biologic treatments. Vera has not yet reported any revenue.</li>
  <li>Their primary patient population is in the United States, targeting those with serious immunological disorders.</li>
</ul>
<p>Vera Therapeutics, Inc. is a biotechnology company that specializes in innovative solutions for immune and kidney diseases. By leveraging advanced biologic technologies, Vera aims to address significant unmet needs in complex patient groups. The company’s emphasis on late-stage clinical development and targeted indications positions it as a potential leader in the immunology therapeutics sector.</p>

<h3>Implications for Investors</h3>
<p>Vera Therapeutics is approaching a pivotal period. Its lead therapy, atacicept, has shown positive results in Phase 3 trials for IgA nephropathy and is awaiting an FDA decision scheduled for July 7, which could pave the way for a U.S. launch soon after.</p>
<p>Financially, Vera ended 2025 with approximately $714.6 million in cash and investments. Additional financing could boost this figure to nearly $800 million, providing ample resources for commercialization and future operations. Although the company posted a net loss of about $299.6 million last year, this is largely attributed to expenses related to late-stage trials and launch preparations, rather than a weakening business outlook.</p>
<p>Within a portfolio already concentrated in biotech names such as Insmed and Revolution Medicines, this investment aligns with a strategy focused on high-conviction positions around clear clinical milestones. Should Vera’s commercialization efforts proceed as anticipated, this move appears well-founded.</p>

<h2>Should You Consider Investing in Vera Therapeutics?</h2>
<p>Before making a decision to invest in Vera Therapeutics, keep the following in mind:</p>
<p>For example, when <strong>Netflix</strong> was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in <strong>Nvidia</strong> from April 15, 2005, would have grown to $1,094,668.</p>
<p>Currently, <em>Stock Advisor</em> boasts an average return of 911%, far outpacing the S&amp;P 500’s 186%. <strong>Don’t miss out on the latest top 10 list, available with <em>Stock Advisor</em>, and join a community of investors focused on individual success.</strong></p>
<p><em>*Stock Advisor returns as of March 20, 2026.</em></p>

Integral Health Asset Management Increases Vera Therapeutics Stake On February 17, 2026, Integral Health Asset Management reported the purchase of 100,000 shares of Vera Therapeutics (NASDAQ:VERA), a transaction valued at approximately $3.55 million based on the average price for the previous quarter. Details of the Transaction As outlined in a SEC filing dated February 17, 2026, Integral Health Asset Management expanded its position in Vera Therapeutics by an additional 100,000 shares. This acquisition, calculated using the average closing price for the quarter ending December 31, 2025, is estimated at $3.55 million. The total value of the holding increased by $41.75 million, reflecting both new share purchases and changes in Vera’s stock price. Key Takeaways Following this transaction, Vera Therapeutics now represents 4.53% of the fund’s 13F assets under management. Top portfolio holdings after this filing include: NASDAQ:INSM – $217.55 million (11.0% of AUM) NASDAQ:RVMD – $95.58 million (4.8% of AUM) NASDAQ:VERA – $91.15 million (4.5% of AUM) NASDAQ:CYTK – $88.96 million (4.5% of AUM) NASDAQ:REGN – $81.05 million (4.1% of AUM) As of the most recent Friday, Vera Therapeutics shares closed at $40.93, marking a 48% increase over the past year—significantly outperforming the S&P 500’s approximate 16% gain during the same period. Vera Therapeutics: Company Overview Market Capitalization $2.9 billion Share Price (as of Friday) $40.93 Net Income (TTM) ($299.6 million) About Vera Therapeutics Vera Therapeutics is dedicated to developing and bringing to market therapies for severe immune-related conditions. Its main drug candidates include atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia. The company operates as a clinical-stage biotech firm, focusing on advancing proprietary biologic treatments. Vera has not yet reported any revenue. Their primary patient population is in the United States, targeting those with serious immunological disorders. Vera Therapeutics, Inc. is a biotechnology company that specializes in innovative solutions for immune and kidney diseases. By leveraging advanced biologic technologies, Vera aims to address significant unmet needs in complex patient groups. The company’s emphasis on late-stage clinical development and targeted indications positions it as a potential leader in the immunology therapeutics sector. Implications for Investors Vera Therapeutics is approaching a pivotal period. Its lead therapy, atacicept, has shown positive results in Phase 3 trials for IgA nephropathy and is awaiting an FDA decision scheduled for July 7, which could pave the way for a U.S. launch soon after. Financially, Vera ended 2025 with approximately $714.6 million in cash and investments. Additional financing could boost this figure to nearly $800 million, providing ample resources for commercialization and future operations. Although the company posted a net loss of about $299.6 million last year, this is largely attributed to expenses related to late-stage trials and launch preparations, rather than a weakening business outlook. Within a portfolio already concentrated in biotech names such as Insmed and Revolution Medicines, this investment aligns with a strategy focused on high-conviction positions around clear clinical milestones. Should Vera’s commercialization efforts proceed as anticipated, this move appears well-founded. Should You Consider Investing in Vera Therapeutics? Before making a decision to invest in Vera Therapeutics, keep the following in mind: For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would now be worth $494,747. Similarly, a $1,000 investment in Nvidia from April 15, 2005, would have grown to $1,094,668. Currently, Stock Advisor boasts an average return of 911%, far outpacing the S&P 500’s 186%. Don’t miss out on the latest top 10 list, available with Stock Advisor, and join a community of investors focused on individual success. *Stock Advisor returns as of March 20, 2026.

This $91 Million Investment Reflects Strong Confidence in a Biotech Firm Awaiting an FDA Ruling This Year

<h2>Understanding Value Stocks: Opportunities and Risks</h2>
<p>Value stocks often trade at lower valuation multiples, offering a cushion against downside risk that growth stocks typically lack. The real challenge, however, is distinguishing between genuinely undervalued companies and those whose low prices reflect underlying business weaknesses.</p>
<p>Even seasoned investors can struggle to separate true bargains from potential value traps. That’s why StockStory was created—to help you identify standout businesses. With that in mind, let’s examine three value stocks facing significant challenges, along with some alternative investment ideas you may want to consider.</p>

<h3>Labcorp (LH)</h3>
<p><strong>Forward Price-to-Earnings (P/E) Ratio:</strong> 14.9x</p>
<p>Labcorp (NYSE:LH) is a global leader in laboratory testing and drug development, performing over 600 million tests annually and playing a role in 90% of FDA-approved drugs in 2023. Its services support healthcare providers, hospitals, pharmaceutical firms, and patients worldwide.</p>
<p><strong>Concerns About Labcorp</strong></p>
<ul>
  <li>Lack of organic revenue growth in the past two years suggests the company may need to rely on acquisitions to expand.</li>
  <li>Operating expenses have outpaced revenue growth over the last five years, leading to a 9.4 percentage point drop in adjusted operating margin.</li>
  <li>Earnings per share have declined at an average rate of 7.2% per year over the past five years, while revenue has remained flat—indicating reduced profitability per sale.</li>
</ul>
<p>Labcorp is currently priced at $264 per share, reflecting a forward P/E of 14.9. </p>

<h3>IQVIA (IQV)</h3>
<p><strong>Forward Price-to-Earnings (P/E) Ratio:</strong> 13.2x</p>
<p>IQVIA (NYSE:IQV) was formed in 2016 through the merger of Quintiles, a clinical research organization, and IMS Health, a healthcare data analytics firm. The company delivers clinical research, data analysis, and technology solutions to help pharmaceutical companies bring new medications to market more efficiently.</p>
<p><strong>Why We’re Cautious About IQVIA</strong></p>
<ul>
  <li>Annual revenue growth of 2.8% over the last two years has lagged behind industry peers, partly due to its already substantial revenue base.</li>
  <li>Constant currency revenue growth has been lackluster, suggesting that customers may not see enough value at current price points.</li>
  <li>Free cash flow margin has dropped by 3.6 percentage points over five years, indicating increased capital requirements amid rising competition.</li>
</ul>
<p>IQVIA trades at $170.25 per share, equating to a forward P/E of 13.2. </p>

<h3>Franklin BSP Realty Trust (FBRT)</h3>
<p><strong>Forward Price-to-Book (P/B) Ratio:</strong> 0.7x</p>
<p>Franklin BSP Realty Trust (NYSE:FBRT), established in 2012, is a specialized real estate investment trust (REIT) that originates and manages a diverse portfolio of commercial real estate debt, secured by properties both in the U.S. and internationally.</p>

<h4>Reasons to Be Wary of FBRT</h4>
<ul>
  <li>Net interest income has grown at just 6.1% annually over the past five years, trailing behind other banks.</li>
  <li>Projected net interest income is expected to fall by 5.7% over the next year, signaling a potential drop in demand.</li>
  <li>Earnings per share have declined over the past three years, raising concerns since long-term stock performance typically tracks EPS trends.</li>
</ul>
<p>FBRT is currently valued at $9.16 per share, or 0.7x forward P/B. </p>

<h2>Top-Tier Stocks for Any Market Environment</h2>
<p><strong>WHILE YOU’RE HERE: Discover the Top 9 Market-Beating Stocks.</strong> The most successful stocks consistently outperform the market, boasting strong revenue growth, expanding free cash flow, and superior returns on capital. These companies have already earned the market’s recognition.</p>
<p>According to our AI-driven platform, there’s still room for growth. See which nine stocks made our list this week—completely free. </p>
<p>Our 2020 picks included now-household names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Kadant, which delivered a 351% five-year return. </p>

Understanding Value Stocks: Opportunities and Risks Value stocks often trade at lower valuation multiples, offering a cushion against downside risk that growth stocks typically lack. The real challenge, however, is distinguishing between genuinely undervalued companies and those whose low prices reflect underlying business weaknesses. Even seasoned investors can struggle to separate true bargains from potential value traps. That’s why StockStory was created—to help you identify standout businesses. With that in mind, let’s examine three value stocks facing significant challenges, along with some alternative investment ideas you may want to consider. Labcorp (LH) Forward Price-to-Earnings (P/E) Ratio: 14.9x Labcorp (NYSE:LH) is a global leader in laboratory testing and drug development, performing over 600 million tests annually and playing a role in 90% of FDA-approved drugs in 2023. Its services support healthcare providers, hospitals, pharmaceutical firms, and patients worldwide. Concerns About Labcorp Lack of organic revenue growth in the past two years suggests the company may need to rely on acquisitions to expand. Operating expenses have outpaced revenue growth over the last five years, leading to a 9.4 percentage point drop in adjusted operating margin. Earnings per share have declined at an average rate of 7.2% per year over the past five years, while revenue has remained flat—indicating reduced profitability per sale. Labcorp is currently priced at $264 per share, reflecting a forward P/E of 14.9. IQVIA (IQV) Forward Price-to-Earnings (P/E) Ratio: 13.2x IQVIA (NYSE:IQV) was formed in 2016 through the merger of Quintiles, a clinical research organization, and IMS Health, a healthcare data analytics firm. The company delivers clinical research, data analysis, and technology solutions to help pharmaceutical companies bring new medications to market more efficiently. Why We’re Cautious About IQVIA Annual revenue growth of 2.8% over the last two years has lagged behind industry peers, partly due to its already substantial revenue base. Constant currency revenue growth has been lackluster, suggesting that customers may not see enough value at current price points. Free cash flow margin has dropped by 3.6 percentage points over five years, indicating increased capital requirements amid rising competition. IQVIA trades at $170.25 per share, equating to a forward P/E of 13.2. Franklin BSP Realty Trust (FBRT) Forward Price-to-Book (P/B) Ratio: 0.7x Franklin BSP Realty Trust (NYSE:FBRT), established in 2012, is a specialized real estate investment trust (REIT) that originates and manages a diverse portfolio of commercial real estate debt, secured by properties both in the U.S. and internationally. Reasons to Be Wary of FBRT Net interest income has grown at just 6.1% annually over the past five years, trailing behind other banks. Projected net interest income is expected to fall by 5.7% over the next year, signaling a potential drop in demand. Earnings per share have declined over the past three years, raising concerns since long-term stock performance typically tracks EPS trends. FBRT is currently valued at $9.16 per share, or 0.7x forward P/B. Top-Tier Stocks for Any Market Environment WHILE YOU’RE HERE: Discover the Top 9 Market-Beating Stocks. The most successful stocks consistently outperform the market, boasting strong revenue growth, expanding free cash flow, and superior returns on capital. These companies have already earned the market’s recognition. According to our AI-driven platform, there’s still room for growth. See which nine stocks made our list this week—completely free. Our 2020 picks included now-household names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Kadant, which delivered a 351% five-year return.

3 Value Stocks We Avoid

<h2>Petrus Trust Company Acquires Stake in LKQ</h2>
<p>In the fourth quarter, Petrus Trust Company, LTA took a new position in <strong>LKQ</strong> (<span class="ticker">NASDAQ:LKQ</span>), purchasing 520,000 shares, as revealed in an SEC filing dated February 17, 2026.</p>

<h3>Details of the Transaction</h3>
<p>The SEC filing shows that Petrus Trust Company’s new holding in LKQ was valued at $15.70 million at the end of the quarter, reflecting both the share purchase and any price changes during the period.</p>

<h3>Key Insights</h3>
<ul>
  <li>LKQ now represents 1.59% of Petrus Trust’s total 13F assets.</li>
  <li>
    <strong>Top reported holdings after this filing:</strong>
    <ul>
      <li>NYSEMKT:SPY – $216.39 million (21.9% of assets under management)</li>
      <li>NASDAQ:MSFT – $72.48 million (7.3% of AUM)</li>
      <li>NYSE:CPAY – $71.38 million (7.2% of AUM)</li>
      <li>NASDAQ:AMZN – $70.99 million (7.2% of AUM)</li>
      <li>NYSE:AON – $50.81 million (5.1% of AUM)</li>
    </ul>
  </li>
  <li>As of the latest Friday, LKQ shares traded at $28.11, a decline of roughly 31% over the past year, significantly underperforming the S&amp;P 500’s 16% gain in the same period.</li>
</ul>

<h3>LKQ at a Glance</h3>
<table>
  <thead>
    <tr>
      <th>Metric</th>
      <th>Value</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Price (as of Friday)</td>
      <td>$28.11</td>
    </tr>
    <tr>
      <td>Market Capitalization</td>
      <td>$7.2 billion</td>
    </tr>
    <tr>
      <td>Revenue (TTM)</td>
      <td>$13.96 billion</td>
    </tr>
    <tr>
      <td>Net Income (TTM)</td>
      <td>$607.00 million</td>
    </tr>
  </tbody>
</table>

<h3>Business Overview</h3>
<ul>
  <li>LKQ specializes in distributing automotive replacement parts, including body panels, bumpers, glass, mechanical components, and specialty items for both vehicles and recreational vehicles.</li>
  <li>The company’s business model centers on distribution, sourcing both new and recycled parts for the automotive aftermarket in North America and Europe.</li>
  <li>LKQ serves a diverse customer base, including collision and mechanical repair shops, car dealerships (new and used), and retail clients across the United States, Canada, and several European countries.</li>
</ul>
<p>As a leading global distributor of automotive parts, LKQ leverages a vast supply chain and distribution network to offer a wide range of new and recycled components. The company’s scale, operational diversity, and broad customer reach provide stability and a competitive edge in the automotive aftermarket industry.</p>

<h3>Implications for Investors</h3>
<p>Despite ongoing strong cash generation, investor attention remains fixed on LKQ’s short-term earnings challenges. The company’s most recent financial results highlight these pressures: fourth-quarter revenue edged up to $3.3 billion from $3.2 billion a year earlier, but net income dropped to $75 million, and diluted EPS fell 50% year-over-year to $0.29. Nevertheless, LKQ generated $1.1 billion in operating cash flow and $847 million in free cash flow for the year.</p>
<p>Management has responded by implementing cost-saving measures expected to yield over $50 million in annual savings, with more than half anticipated this year. The company is also exploring strategic options to enhance shareholder value.</p>
<p>For Petrus Trust, this investment adds exposure to steady aftermarket demand and pricing power, alongside its core holdings in large-cap tech and index funds. The key question is whether LKQ’s margin pressure is a short-term issue or a longer-term challenge.</p>

<h2>Is Now the Time to Buy LKQ Stock?</h2>
<p>Before making a decision to invest in LKQ, consider the following:</p>
<p>The Motley Fool Stock Advisor team recently named their <strong>10 top stocks</strong> they believe offer the best opportunities right now—and LKQ did not make the list. The selected stocks could deliver substantial returns in the years ahead.</p>
<p>For example, when <strong>Netflix</strong> was recommended on December 17, 2004, a $1,000 investment would have grown to $494,747. Similarly, a $1,000 investment in <strong>Nvidia</strong> after its April 15, 2005 recommendation would now be worth $1,094,668.</p>
<p>Currently, Stock Advisor boasts an average return of 911%, far outpacing the S&amp;P 500’s 186%. <strong>Don’t miss the latest top 10 picks—available with Stock Advisor—and join a community of investors focused on long-term growth.</strong></p>
<p>*Stock Advisor returns as of March 20, 2026.</p>

Petrus Trust Company Acquires Stake in LKQ In the fourth quarter, Petrus Trust Company, LTA took a new position in LKQ (NASDAQ:LKQ), purchasing 520,000 shares, as revealed in an SEC filing dated February 17, 2026. Details of the Transaction The SEC filing shows that Petrus Trust Company’s new holding in LKQ was valued at $15.70 million at the end of the quarter, reflecting both the share purchase and any price changes during the period. Key Insights LKQ now represents 1.59% of Petrus Trust’s total 13F assets. Top reported holdings after this filing: NYSEMKT:SPY – $216.39 million (21.9% of assets under management) NASDAQ:MSFT – $72.48 million (7.3% of AUM) NYSE:CPAY – $71.38 million (7.2% of AUM) NASDAQ:AMZN – $70.99 million (7.2% of AUM) NYSE:AON – $50.81 million (5.1% of AUM) As of the latest Friday, LKQ shares traded at $28.11, a decline of roughly 31% over the past year, significantly underperforming the S&P 500’s 16% gain in the same period. LKQ at a Glance Metric Value Price (as of Friday) $28.11 Market Capitalization $7.2 billion Revenue (TTM) $13.96 billion Net Income (TTM) $607.00 million Business Overview LKQ specializes in distributing automotive replacement parts, including body panels, bumpers, glass, mechanical components, and specialty items for both vehicles and recreational vehicles. The company’s business model centers on distribution, sourcing both new and recycled parts for the automotive aftermarket in North America and Europe. LKQ serves a diverse customer base, including collision and mechanical repair shops, car dealerships (new and used), and retail clients across the United States, Canada, and several European countries. As a leading global distributor of automotive parts, LKQ leverages a vast supply chain and distribution network to offer a wide range of new and recycled components. The company’s scale, operational diversity, and broad customer reach provide stability and a competitive edge in the automotive aftermarket industry. Implications for Investors Despite ongoing strong cash generation, investor attention remains fixed on LKQ’s short-term earnings challenges. The company’s most recent financial results highlight these pressures: fourth-quarter revenue edged up to $3.3 billion from $3.2 billion a year earlier, but net income dropped to $75 million, and diluted EPS fell 50% year-over-year to $0.29. Nevertheless, LKQ generated $1.1 billion in operating cash flow and $847 million in free cash flow for the year. Management has responded by implementing cost-saving measures expected to yield over $50 million in annual savings, with more than half anticipated this year. The company is also exploring strategic options to enhance shareholder value. For Petrus Trust, this investment adds exposure to steady aftermarket demand and pricing power, alongside its core holdings in large-cap tech and index funds. The key question is whether LKQ’s margin pressure is a short-term issue or a longer-term challenge. Is Now the Time to Buy LKQ Stock? Before making a decision to invest in LKQ, consider the following: The Motley Fool Stock Advisor team recently named their 10 top stocks they believe offer the best opportunities right now—and LKQ did not make the list. The selected stocks could deliver substantial returns in the years ahead. For example, when Netflix was recommended on December 17, 2004, a $1,000 investment would have grown to $494,747. Similarly, a $1,000 investment in Nvidia after its April 15, 2005 recommendation would now be worth $1,094,668. Currently, Stock Advisor boasts an average return of 911%, far outpacing the S&P 500’s 186%. Don’t miss the latest top 10 picks—available with Stock Advisor—and join a community of investors focused on long-term growth. *Stock Advisor returns as of March 20, 2026.

Automotive Parts Shares Drop 31% as $16 Million Investment Made Amid 50% Annual Profit Decline

<div class="tdb-block-inner td-fix-index"> 
 <p>Global banking operates under strict regulatory standards designed to ensure stability during periods of financial stress. Basel III remains one of the most important frameworks guiding how banks manage liquidity, capital, and risk exposure. As financial institutions adapt to these requirements, they continue to explore technologies that improve efficiency while maintaining compliance.</p> 
 <p>A recent post by SMQKE on X highlights how Ripple’s ecosystem aligns with these regulatory expectations. SMQKE references multiple Ripple documents that explain how XRP can support banks in meeting Basel III requirements by improving cross-border payment efficiency and reducing liquidity constraints.</p> 
 <h2><strong>Basel III and Liquidity Constraints in Banking</strong></h2> 
 <p>Basel III requires banks to maintain sufficient high-quality liquid assets (HQLA) to survive a 30-day stress scenario under the Liquidity Coverage Ratio (LCR). This requirement ensures that banks can meet short-term obligations even during periods of market disruption.</p> 
 <p>However, compliance introduces operational inefficiencies. Banks often rely on pre-funded nostro and vostro accounts to facilitate international payments. These accounts require capital to remain idle across multiple jurisdictions, which limits liquidity and reduces the ability to deploy funds for lending or investment. This trapped capital represents a high cost within traditional correspondent banking systems.</p> 
 <blockquote class="twitter-tweet"> 
  <p>Yes, Ripple and XRP can assist banks in fulfilling Basel III requirements.✅</p> 
  <p>Documented 3x.📝👇 </p> 
  <p>— SMQKE (@SMQKEDQG) <a href="https://twitter.com/SMQKEDQG/status/2034690228535824709?ref_src=twsrc%5Etfw">March 19, 2026</a></p> 
 </blockquote> 
 <p></p> 
 <h2><strong>Ripple’s On-Demand Liquidity Approach</strong></h2> 
 <p>Ripple addresses these inefficiencies through its on-demand liquidity (ODL) solution. The system uses XRP as a bridge asset to enable near-instant settlement between different fiat currencies. This process eliminates the need for pre-funding by allowing institutions to source liquidity on demand.</p> 
 <p>Banks that use this model can convert one currency into XRP and then into another currency within seconds. This approach reduces reliance on intermediary banks and streamlines the settlement process. Ripple’s documentation suggests that this method can significantly lower pre-funding requirements, improving capital efficiency across cross-border transactions.</p> 
 <h2><strong>XRP Within Basel III Regulatory Frameworks</strong></h2> 
 <p>Despite its utility in liquidity management, XRP faces regulatory treatment that affects how banks interact with it directly. Under current Basel guidelines, XRP carries a high risk weight classification, which increases the amount of capital banks must hold against exposure to the asset. This classification limits direct holdings on institutional balance sheets.</p> 
 <blockquote class="twitter-tweet"> 
  <p>We are on X, follow us to connect with us :- </p> 
  <p>— TimesTabloid (@TimesTabloid1) <a href="https://twitter.com/TimesTabloid1/status/1934162718258499855?ref_src=twsrc%5Etfw">June 15, 2025</a></p> 
 </blockquote> 
 <p></p> 
 <p>Even so, XRP can still function as a transactional bridge rather than a held reserve asset. This distinction allows banks to leverage their utility without necessarily maintaining large direct positions, aligning with compliance requirements while still benefiting from efficiency gains.</p> 
 <h2><strong>Bridging Traditional Finance and Blockchain Systems</strong></h2> 
 <p>Ripple positions XRP as a “universal bridge asset” that connects different financial systems and reduces friction in global payments. This concept supports broader efforts to modernize financial infrastructure using blockchain technology.</p> 
 <p>As banks continue to balance regulatory obligations with operational efficiency, solutions that reduce capital lock-up and accelerate settlement remain highly relevant. The integration of blockchain-based liquidity tools reflects an ongoing shift in how financial institutions approach cross-border transactions.</p> 
 <p>XRP’s role in this evolving landscape highlights its potential to complement traditional banking systems rather than replace them, offering a pathway toward faster, more efficient, and more capital-conscious global finance.</p> 
</div>

Global banking operates under strict regulatory standards designed to ensure stability during periods of financial stress. Basel III remains one of the most important frameworks guiding how banks manage liquidity, capital, and risk exposure. As financial institutions adapt to these requirements, they continue to explore technologies that improve efficiency while maintaining compliance. A recent post by SMQKE on X highlights how Ripple’s ecosystem aligns with these regulatory expectations. SMQKE references multiple Ripple documents that explain how XRP can support banks in meeting Basel III requirements by improving cross-border payment efficiency and reducing liquidity constraints. Basel III and Liquidity Constraints in Banking Basel III requires banks to maintain sufficient high-quality liquid assets (HQLA) to survive a 30-day stress scenario under the Liquidity Coverage Ratio (LCR). This requirement ensures that banks can meet short-term obligations even during periods of market disruption. However, compliance introduces operational inefficiencies. Banks often rely on pre-funded nostro and vostro accounts to facilitate international payments. These accounts require capital to remain idle across multiple jurisdictions, which limits liquidity and reduces the ability to deploy funds for lending or investment. This trapped capital represents a high cost within traditional correspondent banking systems. Yes, Ripple and XRP can assist banks in fulfilling Basel III requirements.✅ Documented 3x.📝👇 — SMQKE (@SMQKEDQG) March 19, 2026 Ripple’s On-Demand Liquidity Approach Ripple addresses these inefficiencies through its on-demand liquidity (ODL) solution. The system uses XRP as a bridge asset to enable near-instant settlement between different fiat currencies. This process eliminates the need for pre-funding by allowing institutions to source liquidity on demand. Banks that use this model can convert one currency into XRP and then into another currency within seconds. This approach reduces reliance on intermediary banks and streamlines the settlement process. Ripple’s documentation suggests that this method can significantly lower pre-funding requirements, improving capital efficiency across cross-border transactions. XRP Within Basel III Regulatory Frameworks Despite its utility in liquidity management, XRP faces regulatory treatment that affects how banks interact with it directly. Under current Basel guidelines, XRP carries a high risk weight classification, which increases the amount of capital banks must hold against exposure to the asset. This classification limits direct holdings on institutional balance sheets. We are on X, follow us to connect with us :- — TimesTabloid (@TimesTabloid1) June 15, 2025 Even so, XRP can still function as a transactional bridge rather than a held reserve asset. This distinction allows banks to leverage their utility without necessarily maintaining large direct positions, aligning with compliance requirements while still benefiting from efficiency gains. Bridging Traditional Finance and Blockchain Systems Ripple positions XRP as a “universal bridge asset” that connects different financial systems and reduces friction in global payments. This concept supports broader efforts to modernize financial infrastructure using blockchain technology. As banks continue to balance regulatory obligations with operational efficiency, solutions that reduce capital lock-up and accelerate settlement remain highly relevant. The integration of blockchain-based liquidity tools reflects an ongoing shift in how financial institutions approach cross-border transactions. XRP’s role in this evolving landscape highlights its potential to complement traditional banking systems rather than replace them, offering a pathway toward faster, more efficient, and more capital-conscious global finance.

New Document: Ripple and XRP Can Help Banks Fulfill Basel III Requirements

Explore Bitget's {0} for more cryptocurrency industry news and trading knowledge. Join Bitget now!

News sitemap